

# Technology Assessment

## Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer

**Technology Assessment  
Program**

Final  
January 22, 2009

**Agency for Healthcare  
Research and Quality  
540 Gaither Road  
Rockville, Maryland 2085**

# **Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer**

## **Technology Assessment Report**

**Project ID: CTCC0608**

**January 22, 2009**

### **Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN, SimCRC, and CRC-SPIN Models**

Ann G. Zauber, Ph.D., Amy B. Knudsen, Ph.D., Carolyn M. Rutter, Ph.D.,  
Iris Lansdorp-Vogelaar, M.S., James E. Savarino, Ph.D.,  
Marjolein van Ballegooijen M.D., Ph.D.,  
and Karen M. Kuntz, Sc.D.

<sup>1</sup>*Memorial Sloan-Kettering Cancer Center*, <sup>2</sup>*Massachusetts General Hospital*,  
<sup>3</sup>*Group Health Cooperative*, <sup>4</sup>*Erasmus MC*, and <sup>5</sup>*University of Minnesota*

This report is based on research conducted by the CISNET under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSP233200800231A [MSKCC], HHSP233200800323A [ErasmusMC], HHSP233200800270A [University of Minnesota], and HHSP233200800234A [Group Health Cooperative]). The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decision-makers; patients and clinicians, health system leaders, and policymakers, make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

None of the investigators has any affiliations or financial involvement related to the material presented in this report.

## Acknowledgments

We acknowledge Martin Brown, Ph.D. and Robin Yabroff, Ph.D. of the National Cancer Institute (NCI) for their assistance with obtaining cancer treatment costs using SEER-Medicare data; Joan Warren, Ph.D. and Carrie Klabunde, Ph.D. of NCI for sharing their preliminary analysis of SEER-Medicare data on colonoscopy-related complications; John Allen, M.D. of Minnesota Gastroenterology, Minneapolis, MN and Joel Brill, M.D. of Predictive Health of Phoenix, AZ for their assistance in deriving coding for screening and complications; Beth McFarland, M.D. and Pam Kassing, M.S. of the American College of Radiology for assistance in coding and costs for CT colonography, William Lawrence, M.D. and Kim Wittenberg, M.A. of AHRQ for contextual and administrative assistance, respectively, and William Larson, of the Centers for Medicare and Medicaid Services (CMS) for providing CMS cost data.

## Table of Contents

Abbreviations.....	5
Executive Summary.....	6
Background.....	8
Literature review for CT colonography test characteristics.....	10
Cost-effectiveness analysis .....	13
Figure 1. Graphical representation of natural history of colorectal cancer.....	15
Table 1. Non-CT colonography strategies evaluated in the analysis.....	18
Table 2. CT colonography strategies evaluated in the analysis.....	19
Table 3. Test characteristics used in base-case analysis.....	23
Table 4. Screening test costs.....	25
Table 5. Summary of the risks and costs of screening complications.....	27
Table 6. Net payment for CRC care during 1998-2003.....	28
Table 7. CT colonography test characteristics .....	31
Results.....	32
Table 8A. Undiscounted results – MISCAN.....	35
Table 8B. Undiscounted results – SimCRC.....	36
Table 8C. Undiscounted results – CRC-SPIN.....	37
Table 9. Base-case cost-effectiveness analysis.....	38
Figure 2A. Cost-effectiveness results – MISCAN.....	39
Figure 2B. Cost-effectiveness results – SimCRC.....	40
Figure 2C. Cost-effectiveness results – CRC-SPIN.....	41
Table 10. Threshold analysis on CT colonography test characteristics for strategies with a 6 mm colonoscopy referral threshold.....	42
Figure 3. CT colonoscopy cost thresholds for strategies with a 6 mm colonoscopy referral threshold, efficient frontier.....	43
Figure 4. CT colonoscopy cost thresholds for strategies with a 10 mm colonoscopy referral threshold, efficient frontier .....	44
Table 11. Threshold analysis on CT colonography test characteristics for strategies with a 10mm colonoscopy referral threshold.....	45
Table 12. Threshold analysis on relative adherence with CT colonography.....	46
Table 13. Threshold analysis from the modified societal perspective.....	47
Table 14. Threshold analysis for different levels of anesthesia costs.....	48
Discussion.....	49
Table 15. Literature review of cost effectiveness of CT colonography in US .....	57
Conclusions.....	59
References.....	60
Appendices.....	67
Appendix 1a. Model description – MISCAN.....	68
Appendix 1b. Model description – SimCRC.....	71
Appendix 1c. Model description – CRC-SPIN.....	72
Appendix 2. Comparison of outcomes from the natural history models at age 65.....	74
Appendix 3. Additional outcomes: Average cost-effectiveness ratios (ACER).....	76
Appendix 4. Results for the secondary threshold analyses.....	79
Appendix 5. Results for a cohort of 50-year-olds. ....	84
Appendix 6. Derivation of costs per screening test by point of service.....	86

## Abbreviations that appear in the report

<b>Abbreviation</b>	<b>Definition</b>
ACER	Average cost-effectiveness ratio
AHRQ	Agency for Healthcare Research and Quality
CISNET	Cancer Intervention and Surveillance Modeling Network
CMS	Centers for Medicare and Medicaid Services
CPT	Current procedural terminology
CRC	Colorectal cancer
CRC-SPIN	Microsimulation model of Group Health Cooperative
CT	Computed tomographic
FOBT	Fecal occult blood test
ICER	Incremental cost-effectiveness ratio
MISCAN	Microsimulation model of Memorial Sloan-Kettering Cancer Center and Erasmus MC
SEER	Surveillance, Epidemiology, and End Results Program
SimCRC	Microsimulation model of University of Minnesota and Massachusetts General Hospital
USPSTF	United States Preventive Services Task Force

## **EXECUTIVE SUMMARY**

### **Background**

Despite recent declines in both incidence and mortality, colorectal cancer (CRC) is the second most common cause of cancer death in the United States. CRC screening has been shown to reduce CRC mortality by 15-33% in randomized controlled trials with Hemoccult II fecal occult blood testing (FOBT). Novel CRC screening technologies, such as computed tomography (CT) colonography have been developed but need to be evaluated in terms of their comparability of performance (sensitivity and specificity) in detecting adenomatous polyps and CRC, acceptability to patients, and test-related complications and costs. Accordingly, we conducted a cost-effectiveness analysis of CT colonography and other currently recommended CRC screening strategies.

### **Methods**

We used three microsimulation models from the National Cancer Institute-funded Cancer Intervention and Surveillance Modeling Network (CISNET) consortium to assess the cost-effectiveness of screening for CRC with CT colonography in comparison to the currently recommended CRC screening strategies. We conducted incremental cost-effectiveness analyses by comparing the incremental costs and benefits with the next best strategy after eliminating dominated strategies (i.e., strategies that are more costly and less effective than another strategy or a combination of other strategies). The analysis was from the payer's (CMS) perspective with costs stated as those which Medicare pays. These payments reflect approximately 80% of the allowable charges, including the facility charges (as applicable) and physician services charges. The patient's co-payment is not reflected in the analysis. We conducted a literature review of the evidence for CT colonography to obtain estimates of its sensitivity and specificity for adenomas by size and for cancer. We used the two large scale multi-site CT colonography studies conducted in the United States using current technology and procedures as our main comparators, resulting in two base cases: the Department of Defense study and the National CT Colonography trial. These studies represent the current most promising assessments of CT colonography compared to optical colonoscopy in clinical practice. We used previously developed estimates of the direct medical costs of screening, screening-related complications, and treatment, as well as direct beneficiary costs and time costs associated with screening and treatment to be used in analyses from the modified societal perspective. The CMS payment was approximately \$500 for colonoscopy with no polypectomy. We assumed a per-test CMS payment of \$488 for CT colonography (the national average CMS payment for an abdominal CT, a pelvic CT, and image processing) and assumed that the test would be performed every 5 years with individuals with a lesion 6mm or larger referred for colonoscopy. We performed sensitivity and threshold analyses on the cost, screening interval, size of lesion triggering colonoscopy referral, diagnostic performance, and relative adherence of CT colonography.

### **Results**

Assuming equal adherence across all tests, the screening benefit for 5-yearly CT colonography, measured in terms of discounted life-years gained compared with no screening, was 2-7 life-years lower per 1000 65-year-old individuals than colonoscopy screening every 10 years but comparable to that of 5-yearly flexible sigmoidoscopy plus annual FOBT. At a per test cost of \$488 the overall costs for the CT colonography strategy were higher than all of the other

screening strategies. CT colonography screening could be cost-effective (i.e., be a non-dominated strategy) at per-test cost of \$108 to \$205 per scan depending on the simulation model used and the test characteristics of CT colonography. If the cost per scan were \$179 to \$237, CT colonography screening would have the same cost per life-year gained as colonoscopy (with CMS payment of approximately \$500 for colonoscopy without polypectomy and \$650 for colonoscopy with polypectomy). If screening adherence were higher with CT colonography compared with other screening tests, CT colonography screening could be included among the efficient strategies at the base-case cost estimate.

### **Conclusions**

Based on the analyses from three microsimulation models, screening for CRC with CT colonography every 5 years with referral of individuals with a 6 mm or larger lesion to colonoscopy provides a benefit in terms of life-years gained that is comparable to that of five-year flexible sigmoidoscopy with annual FOBT and slightly lower than colonoscopy screening every 10 years. The cost of CT colonography relative to the benefit derived and to the availability and costs of other CRC screening tests, would need to be in the range of \$108 to \$205 to be a cost-effective alternative to all other available screening modalities, and in the range of \$179 to \$237 to be cost-effective compared to colonoscopy screening with CMS payment of approximately \$500 for colonoscopy without polypectomy and \$650 for colonoscopy with polypectomy.

## BACKGROUND

Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States (1). It is estimated that 148,810 CRC cases will be diagnosed in 2008 with 49,960 deaths. The lifetime risk of being diagnosed with CRC is 5.7% for men and 5.2% for women; the lifetime risk of dying from CRC is 2.3% and 2.1% in men and women, respectively (2). Approximately 70% of CRCs are diagnosed in persons over the age of 65; more than 90% are diagnosed over the age of 50. Only one-third of cases are detected at an early, more curable stage.

The adenoma-carcinoma sequence is considered to be the primary pathway to CRC. In the 1970s the pathologist Basil Morson conceptualized that the adenoma was the precursor lesion for CRC (3). Screening for CRC, and its precursor lesion the adenomatous polyp, can effectively reduce CRC mortality. Randomized trials of CRC screening with a fecal occult blood test (FOBT) show a 15% to 33% reduction in CRC mortality with screening (4-7) and a 20% reduction in CRC incidence (8). Observational studies also show that endoscopic polypectomy can markedly reduce CRC incidence and mortality (9, 10), and randomized controlled trials of screening with flexible sigmoidoscopy are currently in the field (11-13). Despite this demonstrated benefit of CRC screening, participation in CRC screening is only 50% in the US population aged 50 or older (14).

The US Preventive Services Task Force (USPSTF) (15-17), the Gastroenterology Multi-Society Task Force (18-21), and the American Cancer Society (20-22) advocate screening for CRC for asymptomatic average-risk individuals, starting at age 50. In 2002 the USPSTF (15) had concluded that there was insufficient information to recommend one screening strategy over another and recommended a range of screening options including FOBT, flexible sigmoidoscopy (with or without FOBT), or colonoscopy. In November 2008 the USPSTF updated their recommendations to include stopping CRC screening at age 75 for those who had had consistent negative screenings (17). They also recommended screening with a sensitive FOBT (i.e., Hemoccult SENSAs or a fecal immunochemical test), flexible sigmoidoscopy with a sensitive FOBT, or colonoscopy. Hemoccult II and flexible sigmoidoscopy alone were not recommended. The USPSTF decision was informed by microsimulation modeling from two of the Cancer Intervention and Surveillance Modeling Network (CISNET) models used for this report (23).

New CRC screening tests, such as fecal immunochemical test, the DNA stool test, and computed tomography (CT) colonography have been introduced. In 2003 the MISCAN-Colon investigators provided a cost-effectiveness analysis of the fecal immunochemical test to the Agency for Healthcare Research and Quality (AHRQ) for the Centers for Medicare and Medicaid Services (CMS) to inform the decision regarding whether to cover the fecal immunochemical test and, if so, at what payment (24)

<http://www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&id=20>). In 2007, two CISNET modeling groups (MISCAN and SimCRC) conducted a similar cost-effectiveness analysis to that of fecal immunochemical test to estimate the threshold cost for a DNA stool test relative to currently established screening guidelines in response to a request for National Coverage Determination (<http://www.cms.hhs.gov/mcd/viewtrackingsheet.asp?id=212>) on the use of a DNA stool test-version 1.1 (the PreGen-Plus™ test) for CRC screening among average-risk

individuals every 5 years (25). In this report three CISNET modeling groups conducted a cost-effectiveness analysis of CT colonography to estimate a threshold cost for CT colonography relative to currently recommended screening strategies in response to a National Coverage Analysis on the use of CT colonography for CRC screening among average-risk individuals (<http://www.cms.hhs.gov/mcd/viewtrackingsheet.asp?id=220>).

CT colonography (also known as “virtual colonoscopy”) was first described in 1994 by Vining (26) as a CT for the colon. The key conceptual basis for CT colonography arose when it was recognized that thin-slice contiguous abdominal CT images could be reconstructed in software to simulate visualization of the lumen of the colon and create a ‘fly-through’ display presenting polyps as prominent irregularities jutting from the colonic wall. It took a dozen years for this approach to reach the current state of technical maturity. Technological improvements have continued to refine this process. Between 2000 and 2002, commercial multi-row detector CT scanners advanced from 4-row detector devices to 8, 16 and 64-row assemblies, enabling high-speed imaging of the total abdomen within a single breath-hold, thus nearly eliminating motion artifacts that had hampered earlier efforts. Hardware and software innovations also made possible multi-planar displays and 3D dynamic simulations. A last critical contribution was the development of bowel prep procedures that optimized polyp visualization using CT colonography (27). As a colorectal cancer screening test to identify who should be referred onto colonoscopy, CT colonography is minimally invasive, visualizes the entire colon and rectum, requires no sedation, and has high sensitivity for adenomas of size 10 mm or larger or colorectal cancer. However a full cathartic preparation is required as well as stool tagging. In addition the test entails radiation exposure, a small risk of perforation, and additional investigation of extracolonic findings.

The USPSTF recently (17) reviewed the evidence for CT colonography as a screening test in the general population and found insufficient evidence to support recommending CT colonography for general population screening for CRC. The primary concerns were the unknown benefits and harms associated with extracolonic findings and the potential risks of radiation exposure with CT procedures. In contrast, the American Cancer Society, the Gastroenterology Multi-Society Task Force, and the American College of Radiology did include CT colonography for average-risk CRC screening in their guidelines (21, 28). Furthermore the American Cancer Society guidelines (21) recommended that all individuals with lesions 6 mm or larger be referred to optical colonoscopy with repeat CT colonography screening every 5 years. More recently the Blue Cross/Blue Shield Association issued a report from the Technology Evaluation Center stating that CT colonography for the purpose of colon cancer screening meets their criteria to assess whether a technology improves health outcomes (29).

In 1998 CMS began coverage for CRC screening in the general Medicare population. According to Section 42 CFR 410.37 of the Code of Federal Regulations, new CRC screening tests may be included for CMS coverage by publication of a National Coverage Determination. In May 2008 CMS requested a National Coverage Determination for CT colonography (<http://www.cms.hhs.gov/mcd/viewtrackingsheet.asp?id=220>). The Coverage and Analysis Group at the Centers for Medicare and Medicaid Services (CMS) requested this report from The Technology Assessment Program (TAP) at the Agency for Healthcare Research and Quality (AHRQ). AHRQ assigned this report to the CRC CISNET modeling groups. These groups

delivered their draft report to the Medicare Evidence Development and Coverage Advisory Committee (MedCAC) meeting on November 5, 2008 and presented to the committee on November 19, 2008 for the committee's consideration of the National Coverage Determination for CT colonography in the average-risk population. This report is the final report from the CISNET modeling groups for this request.

In this report we first summarize the evidence on the sensitivity and specificity of CT colonography in CRC screening. Using the best evidence for the test parameters, we then conduct simulations to determine what the payment from CMS to providers would have to be for CT colonography in order for it to be considered comparable to other CRC screening tests from a cost-effectiveness standpoint. To accomplish this we use microsimulation modeling to project lifetime costs, life-years gained, and cost-effectiveness ratios for various CRC screening strategies (including CT colonography strategies). To add robustness to the results we use three microsimulation models, each developed independently by modelers affiliated with CISNET (Cancer Intervention and Surveillance Modeling Network) – a modeling consortium funded by the National Cancer Institute that focuses on the use of modeling to improve our understanding of the impact of cancer control interventions (e.g., prevention, screening treatment) on population trends in incidence and mortality. The three simulation models, MISCAN, SimCRC, and CRC-SPIN, incorporate the best-available evidence on the natural history of colorectal disease and the screening test characteristics to project outcomes such as life-years gained compared with no screening. The results of the three models are compared; comparable results strengthen the credibility of the findings. The base-case analysis considers CT colonography every 5 years with referral of an individual with one or more lesions 6mm or larger to optical colonoscopy, using the test characteristics from the Department of Defense study (30) and the National CT Colonography Trial (31). We also assess several other scenarios as sensitivity analyses.

## **LITERATURE REVIEW FOR CT COLONOGRAPHY TEST CHARACTERISTICS**

Test characteristics for CT colonography were assessed from studies in which subjects received both CT colonography and colonoscopy. As CT colonography is a rapidly evolving technology, many of the older studies are generally outdated in assessing test characteristic for CT colonography in use today. Early studies were conducted in polyp-rich cohorts using 2D technology with generally encouraging results (32, 33). However, studies using these technologies in lower prevalence polyp cohorts, such as seen in screening, had less promising results (34-36). Mulhall (37) conducted a systematic review and meta-analysis of 33 CT colonography studies in 6393 patients published from January 1975 to February 2005 and analyzed the findings by mode of imaging, collimation, reconstruction, type of scanner, use of contrast material, the gold standard for comparison, and software used. However, most of those studies were of higher-risk patients and therefore not applicable for an average-risk screening population. Whitlock and colleagues (38, 39) conducted a structured systematic literature review of CT colonography to inform the USPSTF in their assessment of whether to recommend CT colonography screening for the average-risk population. They found that only 4 of the studies in the Mulhall analysis were among average-risk patients. Of these, 3 studies were quite small and used older technologies. The fourth study, the Department of Defense study (30), was included in the Whitlock assessment along with studies by Johnson (40), Kim (41) and the newly

published study reporting the results of the National CT Colonography Trial (31). We used the Whitlock evidence review (38, 39) to identify for our consideration larger prospective studies in the average risk population with all patients offered CT colonography followed by colonoscopy evaluation.

We used the two large scale multi-site CT colonography studies conducted in the United States using current technology and procedures as our main comparators, resulting in two base cases: the Department of Defense study by Pickhardt (30) and the National CT Colonography trial (31). These studies represent the current most promising assessments of CT colonography compared to optical colonoscopy in clinical practice. We did not combine the results of these two studies but rather used each study as a separate base-case scenario. As noted by Whitlock (38) the results of the two studies were too heterogeneous to combine in a meta analysis with differences in sensitivity for 6-9 mm adenomas as well as for specificity. For a sensitivity analysis we also used a retrospective radiological reading by Pickhardt (42) on his original study and a single institution study by Johnson (40) to assess primary 2D versus 3D readings. We did not include the study by Kim (41) in our comparisons due to its small size (n = 96) and the fact that it reported sensitivity and specificity for all polyps rather than for adenomas.

#### Department of Defense Study (30) (Used for base case analysis)

This study was intended to be proof-of-principle that CT colonography could have high test performance in CRC screening. The study accrued 1233 asymptomatic subjects from military facilities from May 2002 and June 2003 for a same-day CT colonography and optical colonoscopy. Subjects completed a rigorous bowel preparation including a standard 24-hour oral administration of sodium phosphate and bisacodyl. Subjects also had a clear-liquid diet plus barium for solid-stool tagging and diatrizoate meglumine and diatrizoate sodium for the opacification of luminal fluid. Three-dimensional endoluminal display was used for the initial detection of polyps on CT colonography, with 2 dimensional views used in assessing suspected abnormalities. Room air was used to insufflate the colon. A 4-channel or 8-channel CT scanner was used. Polyps were measured with electronic calipers on the 3D view. Extracolonic findings were also reported. The CT colonography scans were read by one of six board-certified radiologists prior to the optical colonoscopy, all of whom had read a minimum of 25 CT colonography scans prior to the study. Optical colonoscopy was performed by 17 experienced endoscopists (14 gastroenterologists and 3 colorectal surgeons). Polyps were photographed and measured using a calibrated linear probe. The study protocol used segmental unblinding for the optical colonoscopy. The endoscopist reported the clinical findings by segment and then was told the CT colonography results for that segment. At this point the endoscopist could go back to review the segment to see if any polyps were missed. The polyps detected were recorded for optical colonoscopy before and after the CT colonography results were revealed. All polyps were sent for histological review. A polyp matching algorithm was used to compare CT colonography and optical colonoscopy with matching criteria of polyps being in the same segment or adjacent segments with polyp dimensions within a 50% margin of error.

The test characteristics were given both per patient and per adenoma, with 92% sensitivity of CT colonography for adenomas 10 mm or larger and 86% sensitivity for adenomas 6 mm or larger. Specificity was 96% for patients with adenomas 10 mm or larger and 80% for patients with adenomas 6 mm or larger. Results were not reported for lesions measuring less than 6 mm.

Extracolonic findings deemed to be of high clinical importance were found in 4.5% of subjects. More patients reported greater discomfort with CT colonography (54%) than with optical colonoscopy (38%), while 8% reported equivalent discomfort. General level of satisfaction with CT colonography was rated excellent by 41% of respondents; only 6% and 2% rated their level of satisfaction as fair or poor. Subjects were slightly more likely to state that of the two tests they preferred CT colonography (49% vs. 41%); 9% reported having no preference.

#### National CT Colonography Trial (31) (Used for base case analysis)

This study, sponsored by the American College of Radiology Imaging Network (ACRIN 6664) and the National Cancer Institute, was intended to assess the performance of high-quality CT colonography in general community practice. The study accrued 2600 asymptomatic subjects from 15 study centers from February 2005 to December 2006. Ninety-seven percent (2531) of those accrued completed same-day CT colonography and optical colonoscopy. Bowel preparation included stool tagging, laxative purgation, and fluid tagging. Glucagon was administered prior to CT acquisition and carbon dioxide was used for colon insufflation. Each participating radiologist had interpreted at least 500 CT colonography scans or had participated in a 1.5 day course. All radiologists chosen to participate had to complete a qualifying examination in which they achieved a detection rate of 90% or more for polyps measuring 10 mm or larger. All CT colonography scans were performed with multi-detector scanners with a minimum of 16 rows. The study data were randomly assigned to be read independently with the use of a primary two-dimensional search method (2D image display with 3D endoluminal problem solving) of a primary 3D search method with the addition of 2D display of multiplanar images. Only lesions of size 5 mm or larger were recorded. Same day colonoscopy was performed or supervised by experienced endoscopists without knowledge of the CT colonography findings. Segmental unblinding was not employed. For cases in which CT colonography had detected a polyp 10 mm or larger that was not detected on optical colonoscopy, the patient was advised to have an additional colonoscopy. All lesions 5 mm or larger were centrally reviewed by one experienced gastrointestinal pathologist. Lesion size was determined from the pathology report, unless piecemeal removal was performed, in which case colonoscopy-derived size estimates were used. An algorithm similar to that used in the Department of Defense study was used to match polyps.

Sensitivity was reported both by patient and by adenoma. The per-adenoma sensitivity of CT colonography for adenomas or CRC 10 mm or larger was 84%, which was slightly lower than the estimate from the Department of Defense study (92%). Sensitivity for adenomas 6 mm or larger was 70%. Specificity was 86% for patients with adenomas 10 mm or larger and 88% for patients with adenomas 6 mm or larger. Extracolonic findings were observed in 66% of subjects, but only 16% were considered of clinical importance requiring either additional evaluation or urgent care.

#### Department of Defense Study Primary 2D versus Primary 3D CT Colonography (42) (Used for sensitivity analysis)

The Department of Defense study was performed using primary 3D reading. Earlier studies using 2D reading had not obtained as good test performance as that of the Department of Defense study with 3D readings. Ten radiologists, blinded to polyp findings, conducted a retrospective interpretation of 730 CT scans from the original Department of Defense study using a primary

2D approach (42). The primary 2D results were compared with the primary 3D results from the original trial of 1233. Sensitivity for adenomas 6 mm or larger was 44% with the primary 2D approach, compared with 86% for the primary 3D approach. Sensitivity for adenomas 10mm or larger was 75% versus 92% for primary 2D and primary 3D reads, respectively. With a primary 2D approach, per-patient specificity for 2D at the 10 mm threshold for referral was 98% compared to 97% for the 3D evaluation (NB: these specificity estimates are for all polyps, not for adenomas only).

#### Johnson 2D versus 3D CT Colonography Study (40) (Used for sensitivity analysis)

Johnson (40) conducted a study of 452 asymptomatic subjects with CT scans interpreted using both a primary 2D and a primary 3D approach. The sensitivity of CT colonography for neoplasms 10 mm or larger using a 1.25mm slice thickness were comparable for primary 2D and primary 3D reads (72% versus 73% respectively). However, the range across three readers was wider for the primary 3D reads (67%-78% for primary 2D reads versus 50-83% for primary 3D reads). Specificity for patients with adenomas 10mm or larger was 97-99% for both reading approaches.

All studies of CT colonography characteristics were for a one-time test. No studies to date evaluate repeat screening with a CT colonography. Therefore, we do not have information on the degree to which false-negative test results are random or systematic.

## **COST-EFFECTIVENESS ANALYSIS**

### Overview

We used three existing microsimulation models validated against the best available data (43-46) to assess the effectiveness and cost-effectiveness of CT colonography, in comparison with the currently-recommended CRC screening strategies. Although randomized controlled trials are the preferred method for establishing effectiveness of (screening) interventions, they are expensive and require long follow-up. Accordingly, well-validated microsimulation models may be used to estimate the required resources and expected benefits from different screening policies and inform decision making. The validity of the models is based on clinical incidence data before the introduction of screening (1975-1979 Surveillance, Epidemiology, and End Results [SEER] data) and the size distribution of adenomas in colonoscopy and autopsy studies (47-57). The external validity has further been tested on the results of large (randomized) screening and surveillance studies, such as the Minnesota Colon Cancer Control Study (4), the CoCap sigmoidoscopy study (58), and the National Polyp Study (9, 44). The models also use the same all-cause mortality estimates from the US life tables and colorectal cancer survival data from SEER (59). Finally, the models were able to explain observed incidence and mortality trends in the US when accounting for risk factor trends, screening practice and chemotherapy treatment (46, 60, 61). Using three models (i.e., a comparative modeling approach) adds credibility to the modeling results and serves as a sensitivity analysis on the underlying structural assumptions of the models, particularly pertaining to the natural history of colorectal disease. Through the CISNET consortium, standardized profiles of the each model's structure and underlying model parameters and assumptions are available at <http://cisnet.cancer.gov/profiles/>.

We used the MISCAN, SimCRC, and CRC-SPIN simulation models to calculate the lifetime costs (discounted and undiscounted) and life expectancy (discounted and undiscounted) for a cohort of 65-year-old individuals residing in the US (i.e., eligible for Medicare benefits) under 14 strategies plus no screening. The 14 CRC screening strategies vary by screening test or combination of tests and screening interval. We conducted an incremental cost-effectiveness analysis from the perspective of CMS and discounted future costs and life years 3% annually (62). In this report, simple dominance means that a strategy was more costly and less effective than another strategy, and weak dominance refers to a strategy that is more costly and less effective than a combination of other strategies. Any screening strategy that demonstrated simple or weak dominance was not considered in cost-effectiveness calculations. The relative performance of the remaining strategies was measured using the incremental cost-effectiveness ratio, defined as the additional cost of a specific strategy, divided by its additional clinical benefit, compared with the next least expensive strategy. All non-dominated (efficient) strategies define the efficient frontier and may be cost-effective depending on the willingness to pay for a life-year gained. An incremental analysis, as described, is recommended by the Panel on Cost-Effectiveness in Health and Medicine (62) for competing strategies and will show whether the net benefits of CT colonography are a good value for the resources required compared with the currently available CRC screening strategies. We also conduct analyses of CT colonography compared with no screening, which shows whether the net benefits of CT colonography are a good value for the resources required among individuals who would not be screened at all without the availability of CT colonography.

#### Microsimulation Modeling

The MISCAN, SimCRC, and CRC-SPIN models simulate the life histories of a population of at least 10 million individuals from birth to death. Each model has a natural history component that tracks the progression of underlying disease in the absence of screening. The models share many characteristics; they use similar model inputs and are calibrated to the same data regarding adenoma prevalence, cancer incidence, and stage distribution. These data were collected and processed as part of CISNET and can be considered the best-available data for informing the simulation models. As each simulated individual ages, there is a chance that an adenomatous polyp – a benign precursor lesion that may lead to CRC – develops. One or more adenomas can occur in any individual and each can develop into preclinical CRC (**Figure 1**). The risk of developing an adenoma depends on age, sex, genetic and other propensity factors. The models track the location in the colon and the size of each adenoma, which influence disease progression and the chance of being found by screening.

Adenomas can grow in size over time. Some adenomas eventually become malignant, transforming to stage I preclinical cancer. A preclinical cancer (i.e., not detected) has a chance of progressing through the stages (from stages I to IV) and may be detected by symptoms at any stage. We assume that adenomas are asymptomatic and can only be detected by a screening test.



average to be detected by screening than an individual with a single small adenoma. All polyps that are detected by colonoscopy are removed via polypectomy.

A description of the model structure and assumptions for each model is given in **Appendix 1**. Furthermore the three models are compared with respect to the natural history outcomes for adenomas and colorectal cancer for individuals at age 65 in **Appendix 2**. A detailed description of the underlying parameters of the natural history for each model is given as a model profiler at <http://cisnet.cancer.gov/profiles/> to provide transparency of the models.

#### *Key differences in model structures*

All three microsimulation models were independently developed and subjected to rigorous comparative evaluations prior to this cost effectiveness of CT colonography. Although the models are calibrated to the same data on adenoma prevalence and cancer incidence, the underlying distributions of dwell times (i.e., the total time spent with adenoma and preclinical cancer prior to symptom detection) differ among the three models. A key assumption in the MISCAN model is that there are two types of adenomas: progressive adenomas (adenomas that eventually can become cancer) and non-progressive adenomas (adenomas that cannot become cancer). In the SimCRC and CRC-SPIN models all adenomas have the ability to progress to cancer (although most will not during the lifespan of the individual). An additional difference is that CRC-SPIN models continuous size rather than discrete stages of adenoma size. Although all three models predict similar estimates of adenoma prevalence and CRC incidence, the difference in the adenoma growth assumptions results in different dwell time estimates among the models. In the MISCAN model adenomas and preclinical cancer have been present for 10 years on average before clinical diagnosis, while the estimate is approximately 22 years for SimCRC and 25 years for CRC-SPIN. Little is known about how fast this progression truly occurs. It is estimated that 30% to 50% of the population have one or more adenomas, but it is difficult to measure dwell time in a real population because, by definition, it is the period during which the condition is undiagnosed. As a result of the difference in dwell time, more life-years are gained from screening in the SimCRC and CRC-SPIN models than in the MISCAN model. In the MISCAN model the additional benefit of increasing screening frequency will be greater than that in SimCRC and CRC-SPIN. A summary of each model is in **Appendix 1**, and a more detailed summary is provided for each model at <http://cisnet.cancer.gov/profiles/> including parameters relating to the underlying natural history of colon adenomas and colorectal cancer such as transition probabilities and dwell times.

Another key difference among the models is the distribution of adenomas in the colorectal tract (see **Appendix 2**). In the MISCAN model, adenomas are assumed to have the same distribution as CRCs, while the SimCRC and CRC-SPIN models are calibrated to the distribution of adenomas from autopsy studies. Approximately 30% of CRCs are located in the rectum, while data from autopsy studies suggest that 8-10% of adenomas are located in the rectum. As a result of this difference, the MISCAN model finds strategies involving sigmoidoscopy to be more effective than the SimCRC and CRC-SPIN models, because a larger proportion of adenomas are within the reach of the sigmoidoscope.

### Study Population

We used the natural history models to estimate the distribution of underlying disease for the 65-year-old US population in 2005 in terms of the presence, location, size, and type (adenoma vs. preclinical cancer) of lesions. (See **Appendix 2** for a comparison of the natural history models for age 65). We conducted an analysis of the effect of different screening strategies among a 65-year-old cohort of individuals who have never been screened as our base case.

In reality, many subjects entering the Medicare program will have had CRC screening before age 65. Of those with prior screening, only those without adenomas detected are still eligible for average-risk screening. Adenoma patients should undergo more frequent surveillance with colonoscopy (20) than those with no neoplasia. This means that on average the eligible population for average-risk screening entering Medicare will be at lower risk than an unscreened population. To explore the effect of our using an unscreened population at age 65, we conduct a sensitivity analysis for a 50-year-old cohort.

### Comparison Screening Strategies (Table 1)

In consultation with AHRQ and CMS, we compared CT colonography screening to the basic strategies of screening with FOBT every year, flexible sigmoidoscopy every five years, combinations of FOBT and sigmoidoscopy, and colonoscopy every 10 years (as stated in Section 410.37 of the Federal Register), which are recommended by the USPSTF (17); the American Cancer Society (21, 22), and/or the Multi-Society Task Force (18-21). No screening was also considered. Although double contrast barium enema was included in the older screening recommendations for the USPSTF (15); it was not included in the newer USPSTF recommendations and is not considered in this analysis. Also the stool DNA test, which was evaluated by the CISNET modelers in a cost-effectiveness analysis in 2007 (25) was not included in this cost-effectiveness analysis for CT colonography. We evaluated three FOBTs: Hemocult II, Hemocult SENSA and immunochemical FOBT and two strategies for sigmoidoscopy (with and without biopsy). We used the same strategies considered by the CISNET modelers for the Technology Assessment for stool DNA (25).

**Table 1.** Non-CT colonography strategies evaluated in the cost-effectiveness analysis

Strategy	Abbreviation	Interval, test 1 (y)	Interval, test 2 (y)	Biopsy @ SIG?
No screening	--	--	--	--
Hemoccult II	HII	1	--	--
Hemoccult SENSА	HS	1	--	--
Fecal immunochemical test	FIT	1	--	--
Flexible sigmoidoscopy with biopsy	SIGB	5	--	yes
Flexible sigmoidoscopy	SIG	5	--	no
Hemoccult II, SIG	HII + SIGB	1	5	yes
Hemoccult II, SIG	HII + SIG	1	5	no
Hemoccult SENSА, SIGB	HS + SIGB	1	5	yes
Hemoccult SENSА, SIG	HS + SIG	1	5	no
Fecal immunochemical test, SIG	FIT + SIGB	1	5	yes
Fecal immunochemical test, SIG	FIT + SIG	1	5	no
Colonoscopy	COL	10	--	--

-- indicates not applicable

### CT Colonography Strategies (Table 2)

We compared these screening strategies to CT colonography screening based on the test parameters of the Department of Defense study (30) using 3D imaging as the primary read and the National CT Colonography trial (31) using both 2D and 3D reads. Subjects with lesions 6 mm or larger detected by CT colonography were referred to colonoscopy. Those with no 6 mm or larger polyps detected had a repeat CT colonography in 5 years. The request for the National Coverage Analysis did not specify a repeat screening interval; we used a 5-year to rescreen (21).

In addition to these two base-case scenarios for CT colonography, we conducted a sensitivity analysis in which we explored CT colonography scenarios using primary 2D reads, referral of individuals with 10 mm or larger lesions for colonoscopy, and a 10-year interval for repeat screening (Table 2). We also considered a hypothetical worst-case strategy for CT colonography that had slightly lower test characteristics than all other CT colonography strategies evaluated, selecting either the value reported by Rockett et al (36) or a value lower than any of the two primary studies (including 2D primary reads), whichever was lower.

For the purposes of this report, we assumed that all individuals begin CRC screening at age 65 (i.e., the age at which Medicare eligibility begins in the general population) and end at age 80. Those with adenomas or colorectal cancer detected are assumed to have colonoscopic surveillance according to the Multi-Society guidelines (20, 21) and continue surveillance with no stopping age. The cohort was followed for their lifetimes to a maximum of age 100. The USPSTF has now recommended a stop age for CRC screening of age 75 (17, 23). We used the stopping age of 80 in this report to be consistent with the DNA stool report. We would expect similar ranking of strategies for stop age of 75 as well as 80 given comparable adherence.



that are both less than 10 mm in size will undergo colonoscopy surveillance every 5-10 years (5 years was used for the modeling; a longer interval is also recommended as noted). Individuals with at least one adenoma greater than or equal to 10 mm in size or with 3 or more adenomas will undergo colonoscopy surveillance every 3 years unless the surveillance colonoscopy is normal or only detects one or two adenomas of size <10 mm, then the next surveillance colonoscopy would be at 5 years.

For the base-case analysis we assumed that all individuals are 100% adherent with screening, follow-up, and surveillance procedures. In sensitivity analysis we examined less than optimal adherence to determine if differences in adherence affect our results (*see section on sensitivity analyses*) We specified a stop age of 80 for screening but allowed all individuals with an adenoma detected to continue to have surveillance colonoscopies until a diagnosis of CRC or death from other causes. All simulated individuals were followed until death (or age 100). The life-years gained per scenario were derived relative to no screening.

### CRC Screening Test Characteristics

**Table 3** contains an overview of test characteristics used in our analyses. For all strategies other than CT colonography, test characteristics were taken from those derived for our previous report on stool DNA screening (25). Test parameters are given by person for the FOBTs and by lesion for CT colonography, colonoscopy, and flexible sigmoidoscopy. The sensitivities stated in **Table 3** are based on sensitivities of the test at one point in time. In evaluating a strategy for a program of repeat testing, we assumed conditional independence for all screening tests. In other words, the sensitivity for detecting an adenoma or cancer depended only on the disease status at the time of the screen and did not depend on the test results from previous screening tests. We assume that the test performance characteristics for FOBTs and CT colonography are based on assessment of the whole colorectum. For sigmoidoscopy and colonoscopy, the test characteristics apply to the portion of the colon and rectum reached by the scope.

### CT Colonography Screening Test Characteristics

The test characteristics for CT colonography are based on the literature review described above. As CT technology has changed rapidly, we used the sensitivity and specificity estimates from the two recent large-scale CT colonography screening trials (30, 31) for our base-case estimates. We did not combine the estimates from these two studies because of procedural differences in performing the tests such as segmental unblinding and types of bowel preparation that made the studies less comparable. Also the two studies differed in their estimates of adenoma (6-9mm) sensitivity and specificity (30, 31). Other estimates were evaluated in sensitivity analyses (see section on sensitivity analyses below).

Estimates of sensitivity for adenomas 6-9 mm were not directly available from the published tables but could be derived mathematically. The estimate of sensitivity for adenomas of size 6-9 mm was derived from the Department of Defense and National CT Colonography published tables (30, 31) which provided sensitivity per adenoma by adenoma size of  $\geq 6$ ,  $\geq 7$ ,  $> 8$ ,  $\geq 9$  and  $\geq 10$ mm. The number of adenomas detected by CT colonography for size 10 mm or larger was subtracted from the number of adenomas detected by CT colonography for size 6 mm or larger for the numerator for CT colonography sensitivity for adenomas of size 6-9mm. The number of adenomas detected by optical colonoscopy for size 10 mm or larger was subtracted from the

number of adenomas detected by optical colonoscopy for size 10 mm or larger for the denominator for CT colonography sensitivity for adenomas of size 6-9mm. For the Department of Defense study (30) from the published Table 3 the sensitivity for 6-9 mm adenomas was  $(180-47)/(210-51) = 0.836$  and for the National CT Colonography study from the published Table 4 was  $(189-108)/(270-128) = 0.57$ .

Although we use adenoma specific inputs for CT colonography sensitivity by adenoma size, the outcomes of the model results are based on a per subject classification. For example, if the simulated subject has two adenomas, this patient has two opportunities for an adenoma to be detected and to be referred on for follow-up colonoscopy. The per-patient sensitivity resulting from the models is therefore higher than the per-adenoma sensitivity used as inputs for the models. We have compared the resulting per-patient sensitivity from the models using the Department of Defense and National CT Colonography per-adenoma sensitivities with the reported patient sensitivities and found that the modeled and observed per patient sensitivities compared well.

### CRC Screening Test Characteristics for non-CT colonography

#### *Fecal immunochemical test*

There are multiple fecal immunochemical tests with varying cut points for positivity, number of slides, number of days tested, and preparations reported in the literature. In the 2003 report by van Ballegooijen (24) we reviewed the literature for fecal immunochemical tests, including HemeSelect, Monhaem, Flexsure, Magstream 1000 Hem SP, and Insure. The 2003 report was primarily based on the performance of the Insure test. We updated the estimates for fecal immunochemical testing based on a large study on sensitivity and specificity of the Magstream 1000/ Hem SP fecal immunochemical test (63). The results of the Morikawa study for CRC were 66% sensitivity for CRC and 95% specificity for CRC which were similar to the estimates of sensitivity of 70% and specificity of 95% used in the previous report on fecal immunochemical testing to AHRQ and CMS (24). Consequently we retained the estimates of the test's specificity and sensitivity for cancer from the previous report. However detection rates for adenomas were slightly higher than in the 2003 report. Because the sensitivity estimates for adenomas in the 2003 report were based on limited data, we used the adenoma sensitivity estimates reported by Morikawa (63, 64) for the DNA stool report. A study by Allison (65) for a FlexSure OBT (currently marketed as Hemoccult ICT by Beckman Coulter) had sensitivity for CRC of 82% and for advanced adenomas was 29.5%. Specificity for the fecal immunochemical test was 98%. The test characteristics used in this analysis are within the confidence intervals of this study.

#### *Hemoccult SENSE*

We assumed that the sensitivities of Hemoccult SENSE for adenomas and CRC were similar to those of fecal immunochemical test. However specificity was assumed to be lower for Hemoccult SENSE (24). In addition to yielding more false-positive results, the lower specificity of Hemoccult SENSE results in a greater number of chance findings of adenomas; consequently adenoma detection with SENSE was considered to be slightly higher than with a fecal immunochemical test. In the 2007 study by Allison (65), the sensitivity of Hemoccult SENSE for CRC was 64% (lower than for the fecal immunochemical test comparator) and for advanced adenomas was 41% (higher than for the fecal immunochemical test comparison). Specificity was

98% similar as that for the fecal immunochemical test comparator. Our sensitivity estimates for Hemoccult SENSE are within the confidence intervals of this study. The specificity is significantly higher than assumed in our analysis, but this high specificity is not corroborated by other studies.

### *Hemoccult II*

The estimated CRC sensitivity of Hemoccult II was not changed from the 40% estimated in the 2003 report (24) which was based on a synthesis of the randomized controlled trials (4, 6, 7). This sensitivity is considerably higher than the 13% found by Imperiale (66), but more in line with the 33% that Ahlquist (67) found. One of the reasons for this may be that in the Imperiale study (66) Hemoccult II was not centrally processed. The 40% sensitivity figure is consistent with the randomized trial results according to earlier modeling studies (7, 68) and other Hemoccult II studies (25). Sensitivities of Hemoccult II for adenomas were estimated by assuming the same ratio between adenoma sensitivity and CRC sensitivity as for a fecal immunochemical test.

### *Flexible sigmoidoscopy*

We assumed the same sensitivity for flexible sigmoidoscopy as for colonoscopy within the reach of the scope. The reach of the flexible sigmoidoscopy is generally measured and reported in terms of centimeters of reach rather than location in the colon. However, the models represent adenomas and CRCs by location. We used the correspondence of location and centimeters from the anus from autopsy studies (69) as well as the clinical study of Adam (70) that used an electromagnetic imaging device to record the 3-dimensional position of the scope to estimate the reach for flexible sigmoidoscopy. In a Kaiser Permanente study, 60 cm or more of the colorectum was visualized in 63% of sigmoidoscopies, and at least 40 cm of the colorectum was reached in 83% of sigmoidoscopies (58). We assumed that 80% of sigmoidoscopy examinations reach the junction of the sigmoid and descending colon and 40% reach the beginning of the splenic flexure. For the strategies of flexible sigmoidoscopy every 5 years with an annual fecal occult blood test, we used the test sensitivities for the individual tests.

### *Colonoscopy*

Sensitivity estimates for colonoscopy were based on a recent meta-analysis (71). In screening studies the reach of the colonoscopy has been high with over 90% reaching the cecum. We initially assumed a cecal intubation rate with colonoscopy of 95% in a screening setting. However, guidelines (19) recommend that incomplete colonoscopies are repeated. The 5% incomplete colonoscopies are therefore assumed to be repeated in the models, yielding a total reach of 98% over both colonoscopies. (Note that we did not assume that any of the CT colonography exams would be incomplete, which biases our analysis in favor of CT colonography screening.) We assume that all polyps detected at colonoscopy are removed.

**Table 3.** Test characteristics used in base-case analysis

Test	Sensitivity* by adenoma size or CRC (%)				Specificity (%)
	≤5 mm	6-9 mm	≥10 mm	CRC	
CTC DoD 3D 6mm	--	83.6**	92.2	92.2 <sup>+</sup>	79.6§
CTC NCTC 2D/3D 6mm	--	57.0**	84.0	84.0 <sup>+</sup>	88.0§
Hemoccult II	2.0	5.0	12.0	40.0	98.0
Hemoccult SENSА	7.5	12.4	23.9	70.0	92.5
Fecal immunochemical test	5.0	10.1	22.0	70.0	95.0
Sigmoidoscopy <sup>†</sup>	75.0	85.0	95.0	95.0	92.0‡
Colonoscopy	75.0	85.0	95.0	95.0	90.0‡

CTC = computed tomography colonography; DoD = Department of Defense study (30, 42); NCTC = National CT Colonography Trial (31); -- indicates sensitivity is not provided because size is smaller than the colonoscopy referral threshold of 6mm

\* Sensitivity is provided per individual for stool-based tests and per lesion for endoscopy and CT colonography tests.

\*\*Sensitivity for CT colonography for adenomas 6-9 mm was mathematically derived from published tables as  
+ Sensitivity for CRC was assumed to be the same as for adenomas of size ≥10 mm due to the small number of colorectal cancers detected in the DoD and NCTC studies

§ The lack of specificity with CT colonography reflects the detection of non-adenomatous polyps, artifacts, and adenomas smaller than the colonoscopy referral threshold of 6mm.

<sup>†</sup>Test characteristics for sigmoidoscopy apply only to lesions in the distal colon and rectum.

<sup>‡</sup> The lack of specificity with sigmoidoscopy and colonoscopy reflects the detection of non-adenomatous lesions. With sigmoidoscopy, the presence of non-adenomatous lesions induces biopsy costs (in the case of sigmoidoscopy with biopsy) or results in referral for colonoscopy (in the case of sigmoidoscopy without biopsy). With colonoscopy, non-adenomatous lesions are removed and therefore induce polypectomy and biopsy costs.

## Costs

### *Payer's perspective.*

The base-case cost-effectiveness analysis was from the payer's (CMS) perspective with costs stated as those which Medicare pays. These payments reflect approximately 80% of the allowable charge, including the facility charges (as applicable) and physician services charges. The beneficiary's co-pay is not reflected in the analysis.

We also conducted an analysis from a modified societal perspective by including direct costs borne by beneficiaries as well as estimated patient time costs, but excluding costs due to lost productivity caused by early death or disability.

Screening costs were based on information provided by CMS on Medicare payments in 2007 for procedures and tests associated with CRC screening and complications of screening as reported in the DNA stool test cost –effectiveness analysis (Appendix 4 of that report (25) and replicated here in **Appendix 6**). Net costs of CRC-related care were obtained from an analysis of SEER-Medicare linked data. We did not include the cost of a separate office visit for any of the screening strategies as we assumed that all recommendations or arrangements for screening would already be associated with a previously-scheduled office visit.

The screening test costs are provided in **Table 4**. The costs for FOBT, flexible sigmoidoscopy, colonoscopy, complications of screening, pathology, and of colorectal cancer treatment are those used for the cost-effectiveness analysis of the DNA stool test for CMS (25).

Briefly, screening-related costs were based on the set of current procedural terminology (CPT) codes relevant to CRC screening in conjunction with the points of service for the procedures. 1) in the Ambulatory Surgery Center (ASC) setting, we include the Medicare ASC facility payment and the payment for physician professional services; 2) In the Outpatient Prospective Payment System (OPPS) setting, we include the Medicare OPPS facility payment and the payment for physician services; and 3) in the office setting, we include the payment to the physician for providing the service includes both professional services and the facility costs of the physician's office. We did not include CPT codes of inpatient procedures as registered in the Inpatient Prospective Payment System because screening endoscopies are not typically performed as inpatient procedures. The total costs per CPT code were weighted by the frequencies for points of service. The total costs per screening procedure were based on the total costs per CPT code that are part of the procedure and weighted by the frequencies of the CPT codes. Payments for a procedure across these settings was represented as an average of the three settings weighted by the frequency of which each setting was used for the procedure in 2007.

#### *CT colonography cost per screening episode*

Given that this report was written in conjunction with the National Coverage Determination for CT colonography for CRC screening in the Medicare population, there is no national CMS payment rate for a screening CT colonography at this time. Accordingly, we use as a proxy the national average CMS payment for an abdominal CT without contrast (CPT code 74150), a pelvic CT without contrast (CPT code 72192) and image processing on an independent workstation (CPT 76377). We obtained estimates of the 2008 rates from CMS for these procedures and converted them to 2007 dollars using a decrease of 3.5% in medical care costs to be compatible with the 2007 cost estimates obtained for other screening tests, complications, and colorectal cancer care. This process yielded a base-case cost for CT colonography of \$488.29. We note that this is similar to the average payment for a diagnostic CT colonography among carriers in the NY area (\$486) (personal communication, Bill Larson, Paul Deutch) including professional and technical fees and to an estimate by Pam Kassing of the American College of Radiology of \$487.69.

This base case cost estimate of CT colonography of \$488.29 does not include costs for further radiological evaluations for extracolonic findings. We note that our analyses were based on a Medicare perspective and with Medicare payments, but that in other settings colonoscopy and CT colonography costs may be very different. For example Pickhardt (72) noted that in his institution the CT colonography *charge* was \$1187 and three to four times less than the colonoscopy *charge* (\$3323-\$5000).

**Table 4.** Screening tests costs based on CMS payment (2007 US dollars)

Screening test	CMS cost, \$*	Modified societal cost,** \$
CT colonography†*	488.29	643.64
Guaiaac Hemoccult (II or SENSA)	4.54	21.54
Fecal immunochemical test	22.22	39.22
Flexible sigmoidoscopy	160.78	270.30
Flexible sigmoidoscopy with biopsy	348.19	497.37
Colonoscopy without polypectomy ‡	497.59	794.94
Colonoscopy with polypectomy or biopsy‡	648.52	979.28

\* CMS cost represents approximately 80% of the allowable charge in 2007 dollars.

\*\* Modified societal costs include beneficiary costs (co-payments) and time costs in addition to the payer costs

† Based on CMS payment for CT of the abdomen (CPT 74150), CT of the pelvis (CPT 72192), and image processing on an independent workstation (CPT 76377).

‡ Base case cost for colonoscopy does not include additional anesthesia costs. A secondary sensitivity analysis considers an additional \$74 cost added to colonoscopy for anesthesia in 29% and 100% of colonoscopies

#### *Screening costs for non-CT colonography tests*

Payer cost for Hemoccult II, Hemoccult SENSA, and fecal immunochemical testing do not include additional charges for points of service because these costs are related only to the clinical laboratory fee schedule (<http://www.cms.hhs.gov/ClinicalLabFeeSched/>).

The costs for colonoscopy without polypectomy were based on CPT codes 45378 (diagnostic colonoscopy), G0105 (colon screen in high risk individuals) and G0121 (colon cancer screening for non high risk individual). Costs for colonoscopy with polypectomy or biopsy were composed of codes 45380 (colonoscopy and biopsy), 45381 (colonoscopy, submucous injection), 45382 (colonoscopy/control bleeding), 45383 (lesion removal colonoscopy – fulguration), 45384 (lesion removal colonoscopy-hot biopsy) and 45385 (lesion removal colonoscopy-snare polypectomy). As noted above, if the colon is not adequately visualized, a repeat colonoscopy is typically performed. CMS reimburses the second colonoscopy at the same rate as for the initial colonoscopy. We assumed 5% of the colonoscopies are incomplete and need to be repeated. Instead of modeling incomplete colonoscopies, we increased the costs of a colonoscopy without polypectomy (\$497.59) by 5%, resulting in \$522.47. For colonoscopy with polypectomy we added the same absolute difference of \$25, resulting in \$673.4 (648.52 + 25). The additional \$25 reflects repeat colonoscopies assuming that polyps were only removed at one of the two colonoscopies.

We assumed that polypectomy was not performed with flexible sigmoidoscopy screening. However, we distinguished flexible sigmoidoscopy with and without biopsy. For flexible sigmoidoscopy without biopsy we used CPT codes 45330 (diagnostic sigmoidoscopy) and G0104 (CA screen; flexi sigmoidoscope). Flexible sigmoidoscopy with biopsy was based on CPT code 45331 (sigmoidoscopy and biopsy).

### *Polyp removal and pathology review*

For the procedures with polypectomy or biopsy we included a pathology charge (CPT code 88305). The Medicare payment rates per jar were \$82.40 for the Physician fee schedule office and ASC settings, and \$51.59 for the OPPS setting. We assumed that all biopsies and removed polyps are reviewed by pathology and that a separate jar is submitted to pathology for each of 4 colon segments so that the resection area could be identified should the patient require surgery. Data from the National Colonoscopy Study were used to provide the estimate of 1.38 as the average number of jars per patient with polyps (hyperplastic, other polyps, and adenomas) (personal communication, Ann Zauber, Ph.D.). Consequently, we multiplied the pathology fee by 1.38 to obtain the average pathology cost associated with colonoscopy with polypectomy.

Multiple polyps requiring the same type of polypectomy removal within a single colonoscopy do not add an incremental charge to the procedure. However if different types of polypectomy are required in removing multiple polyps then CMS reimburses 100% for the most expensive procedure and 50% of the facility cost for the second procedure. As a simplifying assumption we use the weights of procedures by CPT type and do not consider different fees for different combinations of endoscopy CPT codes for polyp removal.

### *Anesthesia cost for colonoscopy*

For the base case the cost of moderate sedation was included in the cost of colonoscopy, assuming that it is not administered by an anesthesiologist. Some anesthesia costs such as Monitored Anesthesia Care (MAC) provided by an anesthesia professional such as an anesthesiologist or CRNA are currently being reimbursed in addition to the colonoscopy procedure. The additional CMS payment for the anesthesia was \$74 based on an average cost for the CPT code 00810 in 2007 for monitored anesthesia care for lower endoscopy procedures. (The anesthesiologist receives 5 base units plus one unit for each 15 minutes of service; Joel Brill, personal communication). In 2007, 29% of colonoscopies performed outside a hospital setting for Medicare participants included an additional payment for anesthesia. We use this level as a high estimate for current anesthesia use in colorectal cancer screening. We also considered a strategy where anesthesia was reimbursed in 100% of colonoscopies as a sensitivity analysis of maximum use.

### *Complications of screening*

There are essentially no complications from the stool-based screening tests (Hemoccult II, Hemoccult SENSAs, or immunochemical) from the tests themselves. However patients undergoing colonoscopy and, to a lesser extent, flexible sigmoidoscopy and CT colonography are at risk of experiencing complications from the procedures. Because individuals with a positive sigmoidoscopy, CT colonography or stool-based tests are referred for a follow-up colonoscopy, the complications and the associated costs are relevant and accounted for in all of the screening strategies.

Risks of complications reported in organized screening programs (73-75) are lower than those reported for general practice colonoscopies (76, 77) and have not focused on the older ages. Also risks of complications of colonoscopy have declined over time. The major complications of colonoscopy are perforations, which can occur with or without polypectomy, serosal burns, bleeds requiring transfusion and bleeds not requiring transfusion (73, 75, 77, 78) (personal communication; Drs. John Allen and Joel Brill). Dehydration was also cited as a complication of

colonoscopy in an assessment in the Medicare population (personal communication; Joan Warren, Ph.D. and Carrie Klabunde, Ph.D). All available data were used in deriving the complication rate estimates (**Table 5**). We used the risks and associated costs of complications with sigmoidoscopy and colonoscopy that we derived for the stool DNA report (25) in **Table 5**.

The costs of complications were based on the relevant diagnosis-related group (DRG) codes. For CT colonography we assumed a risk of perforation of 4.56 per 100,000 (79). Although perforations from CT colonography may be less severe than those from colonoscopy we conservatively assumed that 5.19% of those who have a perforation die as a result (80), regardless of which test caused the perforation. Some studies showed that complication rates with colonoscopy are higher in therapeutic than in purely diagnostic colonoscopies (77, 81). However, most studies do not distinguish or have too few numbers to distinguish between therapeutic and diagnostic colonoscopies. We therefore could not confidently decide on a different complication rate for therapeutic and diagnostic colonoscopies and used the same rate for both. Our assumption biases against colonoscopy screening strategies, as they have the lowest percentage of therapeutic procedures. Our estimates for colonoscopy risks are similar to the November 2008 report from a population based study in Canada by Rabeneck (82) with rates of 1.64 per 1000 for bleeding and 0.85 per 1000 for perforation. They are also consistent with the evidence review by Whitlock (38, 39) who stated that complication rates could not be derived for colonoscopies with and without polypectomy because of reporting limitations. Earlier reports on CT colonography perforation risk were in cohorts where air insufflation was the practice; current practice is to use carbon dioxide insufflation with lower risk for perforation (Dr. Zalis, personal communication).

**Table 5.** Summary of risks of CT colonography and endoscopy complications and costs (2007 US dollars)

Complication	Rate per 1000	CMS cost, \$	Modified societal cost, \$
With CT colonography			
Perforation	0.0456	12,446	12,712
With colonoscopy			
Perforation	0.7	12,446	12,712
Serosal burn	0.3	5,208	5,474
Bleed with transfusion	0.4	5,208	5,474
Bleed without transfusion	1.1	320	586
With flexible sigmoidoscopy			
Perforation	0.02	12,446	12,712

#### *Costs for colorectal cancer treatment*

The costs of CRC treatment were also the same as those used in the DNA stool test report (25). Briefly, these costs were derived from comparison of costs for CRC cases relative to those of matched controls in the SEER-Medicare files for the years 1998-2003 (personal communication, Robin Yabroff, Ph.D. and Martin Brown, Ph.D; (83)) and vary by phase of care (**Table 6**).

**Table 6.** Net payments for colorectal cancer care during 1998-2003 (in 2007 US dollars)\*

AJCC Stage	Initial Phase	Continuing Phase	Last Year of Life	
			Died from CRC	Died from Other Causes
<u>Direct medical costs</u>				
I	25,487	2,028	45,689	11,257
II	35,173	1,890	45,560	9,846
III	42,885	2,702	48,006	13,026
IV	56,000	8,375	64,428	34,975
<u>Modified societal costs</u>				
I	32,720	2,719	56,640	17,408
II	43,752	2,561	56,417	15,740
III	53,003	3,573	59,481	19,413
IV	68,853	10,743	78,227	44,384

\* The initial phase of care is the first 12 months following diagnosis, the last-year-of-life phase is the final 12 months of life, and the continuing phase is all the months between the initial and last-year-of-life phases. Cancer-related costs in the continuing phase of care are an annual estimate.

#### *Follow-up costs of extracolonic findings*

We did not include the additional medical costs nor potential net harms or net benefits to follow up of extracolonic findings detected by CT colonography in the base case analyses. Although the prevalence of extracolonic findings has been reported (21), (30), (31) as well as costs (72), the long-term benefit or harm of discovering and working up the various extracolonic findings is not known. The implicit assumption that we are making by not formally incorporating these costs, harms and benefits is that, conditional on a CT colonography examination being done, cost-effective approaches to follow-up care of extracolonic finding are being adopted. However it is not clear from the evidence available today whether this is a valid assumption. In the discussion, we briefly explain the potential consequences of including extracolonic findings for our cost-effectiveness analysis.

#### *Out-of-pocket and time costs*

In a sensitivity analysis we added beneficiary costs (co-payments) and time costs to the payer costs for a modified societal perspective. We label this perspective a “modified societal perspective” because while we include the above costs, we do not incorporate productivity costs. This analysis captures costs and not charges, which are not a good reflection of the opportunity costs of resources required.

Beneficiary costs associated with screening tests were based on the CMS co-payment per point of service and type of CPT code. To incorporate patient time costs associated with CRC screening we assumed that the value of patient time was equal to the median US wage rate in 2007 from the Bureau of Labor Statistics, \$16.64 per hour. We assumed that endoscopy screening requires preparation and recovery. We assumed that the time associated with a colonoscopy procedure was 8 hours, 4 hours with flexible sigmoidoscopy, and 2 hours with CT colonography. Patient time requirements for stool-based screen tests (e.g., Hemocult II, Hemocult SENSEA, and immunochemical) were assumed to be 1 hour. For treatment of any

complication associated with colonoscopy, sigmoidoscopy, or CT colonography, we assumed that patient time requirements would be on average 16 hours. We did not use a more detailed study of time costs associated with colonoscopy (84) because we wanted an equal accounting of time costs for all screening tests. Modified societal costs for screening are given in the right-hand side of **Table 4**.

The beneficiary costs for treatment were also derived based on the copayment and time costs. Estimated patient deductibles and coinsurance expenses were added by adjusting Part A and Part B payments with Medicare payment ratios provided by the CMS Office of the Actuary. Estimates of time costs for cancer care were from a recently published analysis of the SEER-Medicare linked data (85) and updated to 2007 dollars using the Consumer Price Index. The treatment costs that were used as model inputs for the modified societal perspective are shown in the bottom half of **Table 6**.

## Analysis

### *Outcomes*

Using the base-case inputs, we used each model to project a number of outcomes for each screening strategy. These outcomes include the number of cancers detected, life expectancy (discounted and undiscounted) and the lifetime CMS costs (discounted and undiscounted). Differences in results across models reflect the different underlying natural history models. Each model simulated at least 10 million individuals per simulated screening strategy. The results are reported as per 1000 screened.

### *Incremental cost-effectiveness analysis*

For each model, we ranked the 14 screening strategies (no screening, 12 non-CT colonography screening strategies, 1 candidate CT colonography strategy) by increasing effectiveness (i.e., discounted number of life-years gained compared with no screening). Strategies that were more costly and less effective than another strategy were ruled out by simple dominance. Strategies that were more costly and less effective than a combination of other strategies were ruled out by extended dominance. Remaining strategies were then rank ordered by increasing costs and effectiveness, and incremental cost-effectiveness ratios (ICERs) were calculated by dividing the incremental discounted cost by the incremental discounted life-years gained, relative to the next least expensive option. These strategies represent the set of efficient options. On a plot of costs versus life-years gained, a line that connects the efficient strategies is called the efficient frontier, and all dominated strategies (simple or extended) lie below this line (62). If the CT colonography strategy did not lie on the efficient frontier, we then determined the degree to which each of the following parameters would have to change in order for the CT colonography strategy to reach the frontier: unit cost of the CT scan, or relative adherence with CT colonography compared with other screening tests. Because the two base-case CT colonography scenarios do not represent competing options for CT colonography screening but rather two different estimates for test performance, we repeated this process separately for each CT colonography strategy.

### *Threshold analyses*

For each CT colonography strategy, we calculated the maximum cost of a single CT scan for the strategy to be part of the efficient frontier. There were three possible situations to consider when including a CT colonography strategy as an efficient strategy: (1) the CT colonography strategy was less effective than the least effective strategy on the efficient frontier, (2) the CT colonography strategy was more effective than the most effective strategy on the efficient frontier, and (3) the effectiveness of CT colonography strategy was intermediate to the least effective and most effective strategies on the efficient frontier. In the first case the threshold cost of a CT scan was calculated such that the total cost for the CT colonography strategy was the same as the next least effective efficient strategy (yielding an ICER of 0 for that non-CT colonography strategy). In the second case the threshold test cost was calculated such that the ICER for the CT colonography strategy compared with the most effective efficient strategy was equal to \$50,000 per life-year gained. In the third case we identified the efficient strategy with lowest life-years gained that would still have more life-years gained than the CT colonography strategy. Subsequently the threshold cost was calculated such that the ICER of the CT colonography strategy was equal to the ICER of that selected strategy.

Our primary analysis for the threshold value was based on the incremental cost effectiveness ratio (62). These results are presented in the text and tables. We also considered two secondary analyses for the threshold costs. First, we calculated the cost of a single CT scan that would result in the same discounted lifetime cost as no screening. Second, we calculated the per-test cost that would allow a CT colonography strategy to have the same ACER as the colonoscopy ACER where the ACERs represent the incremental cost per life-year saved of each strategy relative to no screening

### *Sensitivity analyses*

We first conducted sensitivity analyses where we evaluated alternative scenarios of CT colonography in terms of test performance according to the primary reading approach (2D, 3D, or both 2D and 3D) and the minimum size polyp detected on CT colonography that will trigger a referral for optical colonoscopy. The test parameters for these sensitivity analyses are given in **Table 7** and are based on data reported in the Department of Defense study (30), the National CT Colonography trial (31), and Johnson 2007 (40) studies. We also considered a hypothetical worst-case scenario that had slightly lower test characteristics than all other scenarios evaluated. The use of 2D for the primary reading of CT colonography does not represent current radiological practice and is only provided as a secondary analysis.

We also conducted sensitivity analyses where we varied relative adherence of CT colonography relative to the other CRC screening strategies. Some have suggested that CT colonography might entice a previously unscreened individual to undergo screening because it is non-invasive (21). Our base-case analysis assumes that 100% of participants adhere to recommendations for the screening tests. To test the impact of differential adherence rates on the threshold CT colonography test cost, we conducted a sensitivity analysis on adherence. We first started with a lower 50% adherence rate for all tests. We assumed that 50% of the population would be 100% adherent with a screening strategy and the other 50% would be non-adherent. Modeling adherence in this fashion allows us to evaluate the impact of enhancing screening with CT colonography in a previously unscreened segment of the population. We then allowed the overall

adherence with the CT colonography strategy to increase from 50% to 55% and 62.5% (where 10% and 25% of unscreened individuals would adopt screening, respectively), and identified the corresponding CT colonography threshold costs per scan. It is assumed that those individuals would be adherent with any recommended follow-up or surveillance colonoscopy.

As noted above, we also conducted sensitivity analysis on adding the anesthesia cost to colonoscopy, 10-yearly CT colonography interval, and when starting screening at age 50 instead of age 65.

**Table 7.** CT colonography test characteristics

CT colonography scenario	Sensitivity* by adenoma size or CRC, %				Specificity <sup>+</sup> (%)
	≤5 mm	6-9 mm	≥10 mm	CRC <sup>†</sup>	
<i>Strategies evaluated in the base-case analysis</i>					
CTC DoD 3D 6mm	--	83.6**	92.2	92.2	79.6
CTC NCTC 2D/3D 6mm	--	57.0**	84.0	84.0	88.0
<i>Strategies evaluated in the sensitivity analysis</i>					
CTC DoD 3D 10mm	--	--	92.2	92.2	96.0
CTC DoD 2D 6mm	--	31.9	75.0	75.0	93.4
CTC DoD 2D 10mm	--	--	75.0	75.0	98.0
CTC NCTC 2D/3D 10mm	--	--	84.0	84.0	86.0
CTC J 3D 10mm	--	--	73.1	73.1	97.6
CTC J 2D 10mm	--	--	72.0	72.0	98.1
CTC WC 2D/3D 6mm	--	30.0	64.0	64.0	78.0
CTC WC 2D/3D 10mm	--	--	64.0	64.0	84.0

-- indicates sensitivity is not provided because size is smaller than the colonoscopy referral threshold of either 6mm or 10mm; DoD = Department of Defense study (30, 42); NCTC = National CT Colonography Trial (31); J = Johnson study(40); WC = hypothetical worst-case scenario

\*Sensitivity is provided per individual for stool-based tests and per lesion for endoscopy and CT colonography tests.

†Sensitivity for CRC was assumed to be the same as for adenomas of size ≥10 mm due to the small number of colorectal cancers detected in the DoD and NCTC studies.

+The lack of specificity with CT colonography reflects the detection of non-adenomatous polyps, artifacts, and adenomas smaller than the colonoscopy referral threshold.

\*\*Sensitivity for CT colonography for adenomas 6-9 mm was mathematically derived from published tables as described in the text above.

## RESULTS

### Projected Undiscounted Outcomes with Screening

Undiscounted outcomes associated with the screening strategies are presented in **Table 8A** for the MISCAN model, **Table 8B** for the SimCRC model, and **Table 8C** for the CRC-SPIN model. Without screening we project that 53 to 60 out of every 1000 65-year old individuals will be diagnosed with CRC in their lifetimes. This induces approximately \$3 to \$4 million in lifetime direct medical costs (\$57 to \$71 thousand per CRC case). With screening and removal of adenomas that may have become cancer over time, many of these CRC cases can be prevented assuming 100% adherence to screening regimens; the reduction in the lifetime risk of CRC ranged from 32-49% with annual FOBT (Hemoccult II) screening to 53-85% with 10-year colonoscopy screening (reported ranges reflect differences in projections by model). Some of the benefit associated with the fecal-related tests is a result of the false-positive rate, which leads to individuals being placed on a colonoscopy schedule. In other words, some of the benefit of these tests can be attributed to the fact that a substantial number of individuals with false-positive test results subsequently undergo screening with 10-year colonoscopy. In the MISCAN model the combination of 5-yearly flexible sigmoidoscopy with an annual highly sensitive FOBT (Hemoccult SENZA or immunochemical) is the most effective strategy in terms of life-years gained compared with no screening, saving 154 life-years per 1000 persons screened. In the SimCRC and CRC-SPIN models, 10-yearly colonoscopy is most effective, saving 171 and 185 life-years per 1000 persons screened, respectively. Five-yearly CT colonography with a 6mm referral threshold and the most optimistic test characteristics (i.e., Department of Defense study) resulted in 2-7 fewer life-years gained per 1000 individuals compared with 10-yearly colonoscopy, with an increase in lifetime (undiscounted) costs of approximately \$600,000-\$700,000 per 1000.

### Cost-Effectiveness Analysis from Payer Perspective

**Table 9** shows the total discounted costs, discounted life-years gained, and the incremental cost-effectiveness ratios for a cohort of 65-year-olds by screening strategy, including no screening, for each model (results for a cohort of 50-year-olds are presented in **Appendix 5**). Note that the incremental cost-effectiveness ratios were calculated using each CT colonography strategy in turn as they are not competing options. The models varied somewhat as to which tests were on the efficient frontier (i.e., were not ruled out by simple or extended dominance). Strategies on the efficient frontier are those strategies with an associated incremental cost-effectiveness ratio and are potentially cost-effective depending on the societal willingness to pay for a life-year gained. All three models showed the CT colonography strategies to be the most costly options. **Figure 2** shows the plots of the discounted life-years gained (compared with no screening), the discounted lifetime direct medical costs (from the Medicare perspective), and the cost-efficient frontier, where each non-dominated strategy is compared with the next least expensive strategy. Hemoccult II was cost-saving compared with no screening for all models. This was the only cost-saving strategy in the MISCAN model. For SimCRC and CRC-SPIN, however, all non-CT colonography strategies were cost-saving compared with no screening. That CT colonography strategies were the most costly can be easily seen from **Figure 2** since for all three models the CT colonography strategies lie to the far right of all screening strategies. Also the CT colonography strategies are more expensive and with fewer life years gained compared to optical colonoscopy for all 3 microsimulation models. Although CT colonography is dominated by the

currently recommended screening options, the costs per life-year gained compared to no screening are below \$10,000 per life-year gained for both base cases and all three models (**Appendix 3**).

### Threshold Analyses

CT colonography generally costs less than optical colonoscopy on a per scan basis but the overall screening strategy for CT colonography screening is more expensive than other screening strategies in general as demonstrated here given comparable adherence. At a cost per test of \$488, none of the CT colonography strategies were on the efficient frontier (**Figure 2**). **Table 10** shows the threshold CT colonography costs under the two base-case scenarios. Threshold analyses indicated that in order for the base-case 5-yearly CT colonography strategies with a 6mm referral threshold to be on the efficient frontier, a CT scan would need to cost between \$108 and \$205 (depending on the test characteristics and the simulation model used). The range of threshold costs required for CT colonography screening to be on the efficient frontier was wider when considering 10-yearly CT colonography strategies with a 6mm threshold, ranging from \$103 to \$371. **Table 10** also presents threshold costs for CT colonography to reach the efficient frontier under different scenarios of the test characteristics for CT colonography (worst-case assumption and 2D reading from the Department of Defense study) with screening interval of 5 years. The threshold costs were much lower than the base-case values, while the 2D Department of Defense analysis was more consistent with the base-case analysis, although the range was wider. **Figures 3 and 4** illustrate threshold cost values graphically with a 6mm referral and a 10 mm referral respectively.

**Appendix 4** also reports the secondary analyses where different criteria were used to calculate the CT scan cost thresholds. Note, that the primary analysis represents the theoretically correct analysis (62). The threshold costs tended to be slightly higher to be cost-neutral compared to no screening. In order for the base-case CT colonography strategies (i.e., 5-yearly screening with a 6mm referral threshold) to have the same average cost-effectiveness ratio (ACER) compared with no screening as the colonoscopy strategy, a CT scan would have to cost between \$179 and \$237 (depending upon the CT colonography test characteristics and the model used).

### Sensitivity Analyses

The threshold costs associated with varying the test characteristics for CT colonography strategies with a 10 mm colonoscopy referral threshold are shown in **Table 11**. Threshold analyses indicated that in order for 5-yearly CT colonography with a 10mm referral threshold to be on the efficient frontier, a CT colonography scan would need to cost in the range of \$98 to \$192 for primary 3D reads, \$49 to \$135 for mixed 2D and 3D reads, and \$73 to \$160 for primary 2D reads (depending on the test characteristics and the simulation model used). Using the secondary criteria to determine thresholds (**Appendix 4**), the threshold costs tended to be slightly higher than the primary analysis (i.e., on the efficient frontier). In no case was the threshold cost greater than the base-case unit cost estimate of \$488.

If individuals who would not be screened otherwise would get screened with CT colonography, its cost-effectiveness would improve. The threshold costs for the test to lie on the efficient frontier under varying adherence assumptions are shown in **Table 12**. With a 10% improvement in CT colonography screening adherence compared with other tests (i.e., 10% of otherwise

unscreened persons adopt CT colonography screening), the CT colonography cost threshold for being on the efficient frontier increased to \$293-\$408. With a 25% improvement in CT colonography screening adherence compared with other tests (i.e., 62.5% overall adherence), the CT colonography cost threshold for being on the efficient frontier increased to \$547-\$694.

**Table 13** contains the results of the threshold analysis from a modified societal perspective. From this perspective the threshold costs that result in a CT colonography strategy reaching the efficient frontier are \$154-\$336 for the 5-yearly testing with a 6 mm referral threshold. These thresholds costs are a bit higher than those from the payer perspective. The higher frequency of Hemocult II and Hemocult SENSA scenarios results in considerably higher additional time costs than with CT screening, allowing for higher per-test costs for the CT colonography scan. The total threshold costs from a modified societal perspective include co-payments and patient time costs. To obtain CMS payment rates the co-payments and patient time costs should be subtracted from the total threshold costs. Assuming no co-payments and patient time costs of \$17 per hour yields CMS payment rates of \$26-\$181 for 5-yearly CT colonography screening with a 6mm referral threshold.

All analyses were conducted for the Medicare population aged 65 years and older assuming no prior CRC screening among this group. To assess the effect of this assumption, we evaluated the cost-effectiveness of the 15 screening strategies for a cohort of 50-year-olds, with screening starting at age 50. Results are presented in **Appendix 5**. The CT colonography strategies remained the most costly of the screening strategies considered. Threshold analyses indicated that in order for 5-yearly CT colonography with a 6mm referral threshold to be on the efficient frontier, a CT scan would need to cost between \$72 and \$179 (depending on the test characteristics and the simulation model used), which was lower than we found in the analysis of 65-year-old individuals.

**Table 14** shows the results of the threshold analysis on the efficient frontier when different percentages of anesthesia costs are included in the cost of colonoscopy. For the MISCAN and SimCRC models the threshold costs for CT colonography decrease by \$0 to \$8 when including more payment for anesthesia cost, whereas for the CRC-SPIN model the threshold costs increase by \$8-\$25. We conclude that even when accounting for 100% payment of anesthesia costs, CT colonography payment thresholds only change slightly. The differences in part relate that the models have different referent strategies on the frontier. Colonoscopy strategy is slightly below the efficient frontier for the MISCAN model. Given that colonoscopy is an integral part of all screening programs, the extra anesthesia cost for colonoscopy affects all screening strategies. Hence, we found that the threshold CT colonography costs changed only slightly with the addition of anesthesia, which was primarily because the strategies that were used as a comparator with the CT colonography strategy has similar numbers of colonoscopy requirements over a lifetime.

**Table 8A.** Undiscounted costs by type, number of life-years gained, and number of cases of CRC per 1000 65-year-olds, by screening scenario – MISCAN

Scenario	Costs (\$)							Outcomes		
	Screening	Follow-Up	Polyp Resection	Surveillance	Complications	CRC Treatment	Total Costs	LYG	SymDx CRC	ScnDx CRC
No screening	0	0	0	0	0	4,030,647	4,030,647	0	57	0
HII	45,577	207,470	86,984	418,620	15,647	2,927,696	3,701,995	116.5	18	21
HS	31,762	370,237	125,488	693,037	26,573	2,501,443	3,748,541	142.8	12	20
FIT	178,116	318,912	116,129	614,068	23,317	2,573,214	3,823,757	141.0	12	21
SIGB	516,641	193,530	115,568	545,450	19,110	2,415,702	3,806,002	132.2	16	14
SIG	378,703	268,592	124,815	633,967	23,143	2,371,694	3,800,914	135.4	15	15
HII + SIGB	471,033	279,361	130,886	665,461	24,154	2,098,139	3,669,035	149.1	11	17
HII + SIG	355,281	333,025	136,711	730,181	26,790	2,275,248	3,857,236	149.9	11	17
HS + SIGB	344,285	398,694	145,073	819,404	30,834	2,016,539	3,754,829	154.1	10	17
HS + SIG	262,997	422,676	147,776	854,913	32,091	2,208,379	3,928,832	154.1	10	17
FIT + SIGB	507,549	356,996	140,678	765,688	28,504	2,229,174	4,028,589	154.3	10	18
FIT + SIG	402,045	391,252	144,355	811,232	30,469	2,219,036	3,998,390	154.3	10	18
COL	776,369	0	152,502	677,187	36,327	2,198,866	3,841,252	151.6	12	15
CTC DoD 3D 6mm 5y	1,007,280	354,666	135,665	748,110	27,561	2,264,920	4,538,212	149.5	11	17
CTC NCTC 2D/3D 6mm 5y	1,129,911	290,386	123,520	644,144	23,369	2,375,757	4,587,088	142.7	13	17

LYG = life-years gained compared with no screening; SymDx CRC = symptom-detected colorectal cancer; ScnDx CRC = screen-detected colorectal cancer

**Table 8B.** Undiscounted costs by type, number of life-years gained, and number of cases of CRC per 1000 65-year-olds, by screening scenario – SimCRC

Scenario	Costs (\$)							Outcomes		
	Screening	Follow-Up	Polyp Resection	Surveillance	Complications	CRC Treatment	Total Costs	LYG	SymDx CRC	ScnDx CRC
No screening	0	0	0	0	0	3,540,411	3,540,411	0	60	0
HII	74,558	189,224	63,882	251,236	11,119	2,213,526	2,803,544	113.9	14	21
HS	121,839	359,983	100,870	409,826	20,408	1,636,905	2,649,832	150.7	8	18
FIT	248,015	305,726	91,444	371,278	17,606	1,711,732	2,745,801	148.3	8	19
SIGB	458,414	129,774	153,495	302,136	11,130	1,795,444	2,850,392	120.6	19	10
SIG	452,330	218,999	82,962	355,829	15,267	1,684,643	2,810,029	128.0	16	10
HII + SIGB	522,284	251,218	168,972	239,952	13,014	1,446,187	2,641,626	157.7	7	15
HII + SIG	529,760	331,172	89,836	255,648	15,279	1,395,290	2,616,985	160.1	7	15
HS + SIGB	437,692	388,531	171,293	417,676	21,751	1,255,331	2,692,275	169.3	6	14
HS + SIG	444,054	442,437	114,584	431,707	23,361	1,231,886	2,688,030	170.2	5	13
FIT + SIGB	628,080	342,482	171,280	366,098	18,916	1,278,827	2,805,683	168.9	6	14
FIT + SIG	638,476	405,523	107,594	379,303	20,723	1,251,488	2,803,107	169.9	5	14
COL	783,430	0	137,876	598,884	32,857	1,124,529	2,677,576	171.3	6	11
CTC DoD 3D 6mm 5y	1,115,618	348,524	114,329	500,485	23,565	1,172,674	3,275,196	168.2	6	12
CTC NCTC 2D/3D 6mm 5y	1,213,047	280,882	101,516	441,470	19,842	1,288,954	3,345,711	160.2	7	12

LYG = life-years gained compared with no screening; SymDx CRC = symptom-detected colorectal cancer; ScnDx CRC = screen-detected colorectal cancer

**Table 8C.** Undiscounted costs by type, number of life-years gained, and number of cases of CRC per 1000 65-year-olds, by screening scenario – CRC-SPIN

Scenario	Costs (\$)							Outcomes		
	Screening	Follow-Up	Polyp Resection	Surveillance	Complications	CRC Treatment	Total Costs	LYG	SymDx CRC	ScnDx CRC
No screening	0	0	0	0	0	2,999,824	2,999,824	0	53	0
HII	80,263	169,980	50,324	200,706	10,036	1,663,309	2,174,619	114.5	17	12
HS	135,166	353,732	83,847	337,414	19,782	1,057,232	1,987,173	155.1	7	11
FIT	267,328	293,055	74,803	302,324	16,660	1,160,290	2,114,460	150.4	8	11
SIGB	478,290	110,463	209,824	269,120	10,365	1,211,533	2,289,595	133.7	17	4
SIG	474,358	206,889	72,375	311,882	14,770	1,079,869	2,160,144	142.2	14	5
HII + SIGB	479,837	221,064	204,285	347,052	15,715	877,095	2,145,048	163.7	7	7
HII + SIG	476,977	289,511	86,877	373,491	18,922	813,753	2,059,531	166.7	7	7
HS + SIGB	420,636	374,095	189,459	415,934	22,787	692,561	2,115,471	175.9	5	7
HS + SIG	425,961	404,518	100,708	426,792	24,437	666,213	2,048,629	176.8	4	7
FIT + SIGB	581,132	320,807	194,795	394,441	20,268	729,944	2,241,386	174.4	5	7
FIT + SIG	567,998	364,345	96,403	411,602	22,497	694,657	2,157,501	175.8	5	7
COL	822,584	0	118,456	506,142	33,208	496,246	1,976,636	184.9	3	5
CTC DoD 3D 6mm 5y	1,202,218	329,204	92,468	398,610	21,994	610,307	2,654,802	177.7	5	5
CTC NCTC 2D/3D 6mm 5y	1,287,352	258,000	83,325	363,894	18,549	686,995	2,698,114	172.2	6	5

LYG = life-years gained compared with no screening; SymDx CRC = symptom-detected colorectal cancer; ScnDx CRC = screen-detected colorectal cancer

**Table 9.** Discounted costs and life-years gained per 1000 65-year-olds without CRC screening and with 14 CRC screening strategies and associated incremental cost-effectiveness ratios


Strategy	MISCAN			SimCRC			CRC-SPIN		
	Discounted Costs (\$)	Discounted LYG	ICER (\$)	Discounted Costs (\$)	Discounted LYG	ICER (\$)	Discounted Costs (\$)	Discounted LYG	ICER (\$)
No Screening	2,714,556	0	d	2,367,514	0	d	1,976,803	0	d
HII	2,631,879	65.7	---	2,082,788	59.9	d	1,536,474	64.0	d
HS	2,715,683	81.1	5,455	2,042,708	81.1	---	1,482,449	87.3	---
FIT	2,777,228	80.1	d	2,116,618	79.8	d	1,574,679	84.7	d
SIGB	2,823,217	75.0	d	2,168,782	65.2	d	1,716,321	75.8	d
SIG	2,810,249	76.7	d	2,151,925	69.1	d	1,626,360	80.4	d
HII + SIGB	2,790,651	84.9	19,381	2,085,889	85.7	d	1,656,317	92.9	d
HII + SIG	2,839,118	85.4	d	2,072,929	87.0	5,147	1,590,434	94.5	d
HS + SIGB	2,859,815	88.0	22,940	2,151,806	92.5	d	1,666,766	99.9	d
HS + SIG	2,907,440	87.9	d	2,150,786	93.0	12,938	1,611,331	100.5	d
FIT + SIGB	3,022,139	88.1	d	2,244,313	92.3	d	1,768,508	99.2	d
FIT + SIG	2,990,860	88.1	988,660	2,244,650	92.8	d	1,699,373	99.9	d
COL	2,906,228	86.7	d	2,173,712	93.8	27,737	1,600,155	105.5	6,465
CTC DoD 3D 6mm 5y*	3,469,661	85.3	d	2,674,721	92.0	d	2,156,740	101.2	d
CTC NCTC 2D/3D 6mm 5y*	3,489,238	81.3	d	2,706,113	87.2	d	2,172,677	98.0	d

--- indicates default strategy (i.e., the least costly and least effective non-dominated strategy)

LYG = life-years gained vs. no screening; ICER = incremental cost-effectiveness ratio; d = dominated


\* The two CTC strategies are not competing options; they represent a range of estimates of CTC test characteristics. They are shown here together for comparison purposes only. The ICERs are assessed separately using each CTC strategy in turn.

**Figure 2, Panel A.** Discounted costs and discounted life-years gained per 1000 65-year-olds for 14 CRC screening strategies\* and the efficient frontier connecting the efficient strategies – MISCAN




\* The two CTC strategies are not competing options; they represent a range of estimates of CTC test characteristics. They are shown here together for comparison purposes only. The ICERs are assessed separately using each CTC strategy in turn.

**Figure 2, Panel B.** Discounted costs and discounted life-years gained per 1000 65-year-olds for 14 CRC screening strategies\* and the efficient frontier connecting the efficient strategies – SimCRC



\* The two CTC strategies are not competing options; they represent a range of estimates of CTC test characteristics. They are shown here together for comparison purposes only. The ICERs are assessed separately using each CTC strategy in turn.

**Figure 2, Panel C.** Discounted costs and discounted life-years gained per 1000 65-year-olds for 14 CRC screening strategies\* and the efficient frontier connecting the efficient strategies – CRC-SPIN



\* The two CTC strategies are not competing options; they represent a range of estimates of CTC test characteristics. They are shown here together for comparison purposes only. The ICERs are assessed separately using each CTC strategy in turn.

**Table 10.** CT colonography unit cost thresholds (in 2007 US dollars) at which CT colonography strategies with a 6mm colonoscopy referral threshold are efficient screening options compared to other recommended CRC screening strategies. CT colonography strategies considered were base cases, sensitivity analysis with a 10-year interval and sensitivity analysis with different estimates of CT colonography test characteristics †


Simulation model	Base cases		Sensitivity analysis, interval 10 years		Sensitivity analysis, test characteristics †*	
	CTC DoD 3D 6mm	CTC NCTC 2D/3D 6mm	CTC DoD 3D 6mm	CTC NCTC 2D/3D 6mm	CTC WC 2D/3D 6mm	CTC DoD 2D 6mm
MISCAN	122	108	52	83	25	98
SimCRC	199	183	266	241‡	83‡	163‡
CRC-SPIN	196	205	352	371	173	246

† See Table 7 for the test characteristics used in these scenarios

\* 5 yearly CT colonography screening interval


‡ CTC strategy is on the frontier as the least effective and least costly non-dominated strategy if the cost is at most this amount

**Figure 3.** CT colonography unit cost thresholds (in 2007 US dollars) at which CT colonography strategies with a 6mm colonoscopy referral threshold are efficient screening options compared to other recommended CRC screening strategies



CTC = computed tomography colonography; DoD = Department of Defense Study (30, 42); NCTC = National CT Colonography study (31); WC = hypothetical worst-case scenario  
 \* CTC strategy is on the frontier as the least effective and least costly non-dominated strategy if the cost is at most this amount

**Figure 4.** CT colonography unit cost thresholds (in 2007 US dollars) at which CT colonography strategies with a 10mm colonoscopy referral threshold are efficient screening options compared to other recommended CRC screening strategies



CTC = computed tomography colonography; DoD = Department of Defense Study (30, 42); J = Johnson study (40); NCTC = National CT Colonography study (31); WC = hypothetical worst-case scenario  
 \* CTC strategy is on the frontier as the least effective and least costly non-dominated strategy if the cost is at most this amount

**Table 11.** CT colonography unit cost thresholds (in 2007 US dollars) at which CT colonography strategies with a 10mm colonoscopy referral threshold are efficient screening options compared to other recommended CRC screening strategies †

Simulation model	Sensitivity analysis scenarios with 10mm colonoscopy referral thresholds					
	Primary 3D reads		2D/3D reads		Primary 2D reads	
	CTC DoD 3D 10mm	CTC J 3D 10mm	CTC NCTC 2D/3D 10mm	CTC WC 2D/3D 10mm	CTC DoD 2D 10mm	CTC J 2D 10mm
MISCAN	98	71	49	10	75	73
SimCRC	192‡	153‡	135‡	81‡	160‡	154‡
CRC-SPIN	132‡	105‡	90‡	43‡,	110‡	105‡

CTC = computed tomography colonography; DoD = Department of Defense Study (30, 42); J = Johnson study (40); NCTC = National CT Colonography study (31); WC = hypothetical worst-case scenario

† See Table 7 for the test characteristics used in these scenarios

‡ CTC strategy is on the frontier as the least effective and least costly non-dominated strategy if the cost is at most this amount

**Table 12.** CT colonography unit cost thresholds (in 2007 US dollars) at which CT colonography strategies with a 6mm colonoscopy referral threshold are efficient screening options compared to other recommended CRC screening strategies for different levels of adherence with CT colonography screening

Simulation model	Base case (CTC DoD 3D 6mm 5y)	Sensitivity Analysis on CTC Adherence†	
	Adherence 50% for all strategies	CTC adherence 55%	CTC adherence 62.5%
MISCAN	122	293‡	547‡
SimCRC	199	408‡	694‡
CRC-SPIN	196	360‡	668‡

CTC = computed tomography colonography; DoD = Department of Defense Study (30, 42);

† Strategies other than CTC remain at 50% adherence

‡ CTC strategy is on the frontier with an incremental cost-effectiveness ratio (ICER) of \$50,000 if the cost is at least this amount

**Table 13.** CT colonography unit cost thresholds (in 2007 US dollars) at which CT colonography strategies with a 6mm colonoscopy referral threshold are efficient screening options compared to other recommended CRC screening strategies for modified societal perspective

Simulation model	Total threshold costs (includes co-payments and patient time costs)		CMS payment rates (excludes co-payments and patient time costs)	
	CTC DoD 3D 6mm	CTC NCTC 2D/3D 6mm	CTC DoD 3D 6mm	CTC NCTC 2D/3D 6mm
MISCAN	181	154	26	NT
SimCRC	332	324	177	169
CRC-SPIN	318	336	163	181

CTC = computed tomography colonography; DoD = Department of Defense Study (30, 42); NCTC = National CT Colonography study (31)

**Table 14.** CT colonography unit cost thresholds (in 2007 US dollars) at which CT colonography strategies with a 6mm colonoscopy referral threshold are efficient screening options compared to other recommended CRC screening strategies for different levels of payment of anesthesia costs

Simulation model	Base case (CTC DoD 3D 6mm 5y)	Sensitivity Analysis on anesthesia payment	
	No payment	29% payment	100% payment
MISCAN	122	119	114
SimCRC	199	199	198
CRC-SPIN	196	204	221

CTC = computed tomography colonography; DoD = Department of Defense Study (30, 42)

## DISCUSSION

### Summary of Results

We used three independent microsimulation models to evaluate the cost-effectiveness analysis of CT colonography in comparison with the currently recommended CRC screening tests of colonoscopy, flexible sigmoidoscopy, and FOBT (guaiac Hemoccult II and SENSEA, and immunochemical). The analysis is based on a cohort of previously unscreened 65-year-old individuals followed over their lifetimes and is conducted from both the CMS payer perspective and a modified societal perspective. We evaluated two recent large-scale CT colonography studies as our base case with referral to optical colonoscopy for a CT colonography-detected lesion of 6 mm or larger diameter and with repeat screening with CT colonography every 5 years. Sensitivity analyses were conducted for referral of individuals with only larger lesions (10 mm or larger) and for longer repeat screening intervals (10 years) as well as for worse case test parameters. Even though the life-years gained by 5-yearly CT colonography with a 6 mm referral for optical colonoscopy were slightly lower than those from colonoscopy screening every 10 years, the overall costs of both base case CT colonography strategies were higher than all of the other screening strategies considered and were dominated. However if CT colonography payment costs were relatively lower than that of colonoscopy, or CT colonography adherence was differentially higher than for other CRC screening tests, including colonoscopy, then screening with CT colonography would be a cost-effective alternative. These findings are based on Medicare payment rather than on allowable charges which would be higher to account for patient copays.

At first it may seem surprising that CT colonography, based on the best evidence available to date, was not cost-effective when compared with the other CRC screening tests since the CT colonography sensitivity for the larger adenomas (10 mm or larger) and CRC is almost comparable to that of optical colonoscopy and the cost for CT colonography per scan was slightly less than that of optical colonoscopy. However, the strategy of CT colonography screening is not a single test but a two-step procedure with those with 6 mm or larger polyps referred to optical colonoscopy. In addition, repeat screening is every 5 years rather than every 10 years as for colonoscopy. Thus for people who never had an abnormality detected, the costs of CT colonography accrues twice as often as the cost of optical colonoscopy. For those who have a positive finding on CT colonography, they accrue the cost of a diagnostic colonoscopy as well as the cost of the screening CT colonography. Consequently the aim of this analysis was also to explore the conditions under which CT colonography (or for that matter any other new test) could be considered cost-effective compared with the existing screening tests. We therefore conducted threshold analyses to determine what a CT colonography would have to cost in order for one of the CT colonography strategies to lie on the efficient frontier (i.e., be a non-dominated strategy). CT colonography screening could be cost-effective (i.e., be a non-dominated strategy) at a cost of \$108 to \$205 per scan depending on the simulation model used and the test characteristics of CT colonography. If the cost per test were \$179 to \$237, CT colonography would provide additional years of life at the same cost per year as colonoscopy (with CMS payment of approximately \$500 for colonoscopy without polypectomy and \$650 for colonoscopy with polypectomy).

We conducted sensitivity analyses to address the question of whether with increased adherence CT colonography would be on the efficient frontier. For this analysis we assumed that adherence was 50% for the currently-recommended tests and that there was increased adherence with the CT colonography test strategies among the unscreened individuals. If screening adherence were higher with CT colonography compared with other screening tests, CT colonography screening could be included among the efficient strategies at the base-case cost estimate of \$488. However this is a hypothetical situation. To date we do not know of a clinical study that has demonstrated that the addition of CT colonography to the currently available screening tests will increase the overall population screening rates by increasing adherence in those previously unwilling to be screened.

We assumed that all in the cohort of 65-year-old individuals were previously unscreened. In reality, many subjects entering the Medicare program will have had CRC screening before age 65. Of those with prior screening, only those without adenomas detected are still eligible for average-risk screening. Adenoma patients should undergo more frequent surveillance with colonoscopy (20) than those with no neoplasia. This means that on average the eligible population for average-risk screening entering Medicare will be at lower risk than an unscreened population. Accordingly we may have overestimated the life-years gained from screening. However, this holds for all tests and strategies and is therefore not expected to significantly influence our results, because the relative performance of one test over the other remains the same. We assessed the potential effect of the assumption of an unscreened 65-year-old population by determining threshold costs for CT colonography screening when screening a 50-year-old cohort from age 50 onwards; the results did not change substantially. Furthermore, we investigated the impact that our assumption of a previously unscreened population would have, by estimating the threshold costs of CT colonography for a 65-year-old cohort at 50% lower risk for one of the models (MISCAN). We found that threshold costs for CT colonography did not change by more than \$8. The direction and magnitude of the change depended on the base case strategy considered. Thus, we expect that the threshold cost would be similar for a population that has been previously screened compared to those of our baseline analysis using a previously unscreened population.

#### Cost-effectiveness of Currently Recommended Test Strategies

As reported in the DNA stool test report to CMS, (25) an important finding from our analysis is that the currently recommended CRC screening tests provide good value for the resources spent. Hemoccult II, the test proven in randomized controlled trials to reduce CRC mortality by 15-33%, with a \$4.54 CMS payment, is cost-saving relative to no screening but with the lowest life years gained with screening. Other FOBTs as well as flexible sigmoidoscopy and colonoscopy provided additional life-years gained over Hemoccult II, often with reasonable costs. Our favorable cost-effectiveness result for the CRC screening strategies is likely due to the increasing costs of CRC-related care and the costs of the screening tests not increasing at the same rate or even lower than previously reported. In this analysis all the costs come from the same source: Medicare payment. The costs for treating CRC stage III and IV and incurable CRC have been increasing since the introduction of newer therapies. The reason that the SimCRC and CRC-SPIN models found more cost-saving strategies than the MISCAN model is likely due to the fact that they find a greater reduction in cancer incidence with CRC screening because of their longer dwell times.

### Evaluation of New Screening Tests in Relationship to Current Recommendations

CRC screening guidelines from the Multi-Society Task Force were published in 1997(18) for currently available tests but the authors also considered how to evaluate new screening tests as well. The guidelines state that a newer test could be substituted for a currently recommended test (or added to the recommendations) if evidence were available to demonstrate that the new test had: (1) a comparable performance for sensitivity and specificity in detecting cancer or adenomatous polyps at comparable stages, (2) was equally acceptable to patients, and (3) had comparable or lower complication rates and costs (18). We address each of these issues below on the strength of the evidence as a screening test and include how the results from the microsimulation modeling are informative for these issues.

#### *Comparability of CT colonography sensitivity and specificity in detecting colorectal cancer and adenomas to other screening tests such as colonoscopy*

The sensitivity of CT colonography varied for the two base cases with the Department of Defense study (30) having comparable sensitivity to detect adenomas 6 mm or larger and colorectal cancers as optical colonoscopy but with the larger community-based National CT Colonography trial (31) having lower sensitivity than that of optical colonoscopy. Adenomas of size <6 mm are not reported at all for CT colonography (86). The natural history of adenomas <6 mm is not well known (72, 87, 88). The risk of high-grade dysplasia or invasive CRC is lower in these smaller adenomas than those  $\geq 6$  mm but the smaller lesions are also the most common. Repeat CT colonography screening at 5-year intervals with referral to optical colonoscopy for those lesions of larger size is one way to offset the optical colonoscopy screening strategy of removing all polyps.

The specificity of CT colonography also varied for the two base cases, with the Department of Defense study (30) having lower specificity (80%) than the National CT Colonography trial (88%) (31). Lack of specificity is also a factor in optical colonoscopy which detects and removes hyperplastic and other polyps as well as the adenomas less than 6 mm in size. In the analyses we assumed 90% specificity for optical colonoscopy to take into account the detection and removal of non-adenomas in optical colonoscopy screening.

The clinical evidence to date has primarily been for a single point-in-time assessment of CT colonography. Information on programmatic use of CT colonography (i.e., repeated screening) is not yet available. Future studies are needed to assess repeat screenings and the impact of a programmatic adherence of CT colonography.

The evidence shows that there is a strong learning curve for CT colonography and that readers must have standardized rigorous training and proper technique to obtain the test characteristics that we used in our analyses, based on two well-designed trials. Quality measures for CT colonography are in development (28).

CT colonography has improved rapidly in the past decade. In Mulhall's meta-analysis, primarily composed of the earlier studies, the sensitivity increased with a decrease in CT colonography slice thickness, use of multidetector CT scanners, and concomitant 2D and 3D imaging (37). Additional improvements in CT colonography are to be expected. However new techniques or

modifications of older techniques must be evaluated as to their test performance characteristics. An assessment of sensitivity and specificity with respect to specific improvements in CT technology was beyond the scope of this report.

Additional techniques are demonstrated for optical colonoscopy to detect flat adenomas (89) and the clinical importance of flat adenomas has been discussed (90). The CT colonography literature has also discussed detection of flat lesions (91, 92). In a retrospective review of the National Polyp Study O'Brien (93) noted that a large percent of small (<6 mm) sessile adenomas detected by colonoscopy without additional techniques would now be classified as flat lesions. However, flat depressed lesions would be likely to be missed by both optical colonoscopy and CT colonography. Additional techniques to detect flat adenomas have not been included in the modeling for this report.

We use three independently developed microsimulation models to project the life-years gained and the lifetime costs associated with CT colonography strategies compared with other currently recommended CRC screening strategies. CT colonography screening, with referral to colonoscopy of 6 mm lesions and with a 5-year screening interval, provides life-years gained slightly lower to that of optical colonoscopy repeated every 10 years and more comparable to that of a program of flexible sigmoidoscopy with FOBT. The life years gained are greater for the CT colonography base case from the Department of Defense than for that from the National CT Colonography Trial for all three microsimulation models.

#### *Acceptability to patients as a screening test*

The currently-recommended CRC screening tests all require considerably more patient involvement than screening tests for other diseases. The individual undergoing screening must complete a cleansing bowel prep for colonoscopy, flexible sigmoidoscopy as well as for CT colonography, restrict their diet for Hemoccult II, colonoscopy, and CT colonography; and restrict NSAID use with Hemoccult II; have contact with the stool for any of the FOBTs; and go to a medical setting for colonoscopy, flexible sigmoidoscopy, or CT colonography. Colonoscopy procedures have a small but real risk of perforations and due to sedation, require an escort to and from the procedure. Although CT colonography is non-invasive it does require a cathartic bowel preparation just as for optical colonoscopy, as well as stool tagging. In addition, a positive CT colonography requires referral for optical colonoscopy as is the case for other two-step procedures. Whether same-day CT colonography and optical colonoscopy for those with a positive CT colonography is possible in the general medical practice is not yet known although there is discussion of this as a practice model (94). If not, then the referred patient must undergo two cathartic preparations. The patient impression is often that CT colonography is 'virtual' and non-invasive. It is not known whether the adherence to optical colonoscopy referral for those with positive CT colonography will be as high or higher as those with positive findings on other CRC screening tests. Although non-cathartic preparations have been developed for CT colonography (95, 96) they involve both dietary restriction over a number of days and ingestion of various oral contrast agent (97). Consequently, the non-cathartic preparations are not 'prepless'. Also same-day optical colonoscopy cannot be performed in those with non-cathartic preparations if the CT colonography is positive for lesions of size 6 mm or larger.

There is a low level of radiation exposure with CT colonography. The long-term effects of cumulative exposure to radiation that would be associated with interval screening with CT colonography are unknown (98, 99). In addition, concern for radiation risk on part of patient or physician could affect willingness to adhere to CT colonography screening.

Patient-stated preference for CT colonography relative to other CRC screening tests has been investigated in those who have had CT colonography. Pickhardt conducted a survey of patient preferences for repeat CT colonography versus repeat optical colonoscopy (30) and demonstrated a slight preference for CT colonography. Gluecker (100) addressed patient preferences for those having CT colonography and colonoscopy versus those with CT colonography and double contrast barium enema; CT colonography was preferred. Bosworth (101) reported that patients who completed optical colonoscopy, CT colonography, and barium enema preferred optical to virtual colonoscopy. Schwartz (102) reported that in a tertiary care center (University of Wisconsin) that the successful initiation of a screening CT colonography program did not result in a decrease in the number of total colonoscopy examinations or screening colonoscopies. These findings could suggest that those having CT colonography screening examinations might have been drawn from those who had not had prior CRC screening. However, prior screening history was not reported in that study. Also as a tertiary care referral center, it is difficult to determine screening rates in a population and whether the rate of no screening decreased. Further studies of patient preference (and adherence) for CT colonography versus optical colonoscopy for the initial screen and of the willingness to have optical colonoscopy if CT colonography is positive are needed, especially among subjects who have been unwilling to perform any of the current CRC screening tests (21).

The US Preventive Services Task Force suggested that CT colonography could be an important option in a colorectal cancer screening program if this test was accepted by subjects who would have otherwise refused other colorectal cancer screening options (17). Our analysis shows that CT colonography screening would need to change screening participation in approximately 10-20% of individuals who would otherwise remain unscreened in order for CT colonography to be cost-effective at a payment rate similar to that for colonoscopy without polypectomy. Further research on CRC screening adherence, including how such adherence is affected by the availability of CT colonography, and willingness to complete optical colonoscopy to evaluate a positive CT colonography test is needed. In our base case analyses we assumed 100% adherence for all phases of testing but we also recognize that in practice that follow up of positive tests is less than 100%.

#### *Evidence on comparable or lower complication rates and costs*

There are perforation complications associated with CT colonography but at a lower rate and with less substantial level of complications as colonoscopic complications (38). There is radiation exposure with CT colonography but at a low level. The harm of low-level radiation has been difficult to assess. Furthermore followup of extracolonic findings detected on CT colonography does contribute to a higher cumulative dose of radiation exposure that should be taken into account (21, 98). Risk may be small, but certainly is not negligible.

#### Cumulative radiation exposure

CT colonography is associated with exposure to radiation. Brenner (98) estimated that the excess

cancer risk from a pair of CT colonography scans using typical current scanner techniques is about 0.14% for a 50-year old and half that for a 70-year old. This estimate is controversial, because it was based on simulation calibrated to atomic bomb survivors. Multiple CT colonography screens will increase the radiation dose proportionally and most likely also the radiation risks. We found in our microsimulation modeling analysis that CT colonography is only compatible to colonoscopy screening if offered seven times (every 5 years between ages 50 and 80), potentially leading to an excess cancer risk of approximately 0.47%. This will lead to life-years lost due to CT colonography which are not negligible compared to the life-years gained. We did not take these excess cancer cases into account. The US Preventive Services Task Force cited lack of knowledge as to whether the radiation exposures associated with CT colonography represented a net benefit or a net loss as to not currently recommend CT colonography for colorectal cancer screening in the average risk population (17, 38). There is good evidence that radiation dose with CT colonography can be reduced by at least a factor of 5 (and perhaps as much as 10), while still maintaining sensitivity and specificity for polyps larger than approximately 5 mm (103). Automatic exposure control options on the latest generation of scanners may facilitate reducing CT-related doses (99). The latest colorectal cancer screening guidelines from the American College of Radiology stress the appropriate use of low-dose protocols for CT colonography in screening (28). With these dose reductions, excess risk of cancer from CT colonography could be reduced.

#### Extracolonic findings

Although CT colonography has been developed as a screening tool to detect colorectal adenomas and CRC, extracolonic lesions are also unavoidably visible (and therefore screened) on the CT colonography scans. There is considerable discussion as to whether the extracolonic findings with CT colonography represent an asset or liability (72, 104, 105). Some of the extracolonic findings include abdominal aortic aneurysms and extracolonic cancers. A one-time screening for abdominal aortic aneurysms is recommended by the USPSTF with ultrasonography only for men age 65 to 75 who have ever smoked (106). An evaluation of the harms and risks of detecting extracolonic lesions is beyond the scope of this report. In our base case analysis we did not include the costs of detecting and evaluating extracolonic findings because we could not also include the harms and benefits. However the implicit assumption that we are making by not formally incorporating these costs, harms and benefits into the analysis is that, conditional on a CT colonography examination being done, cost-effective approaches to follow-up care of extracolonic findings are being adopted. It is not clear at this time whether this is a valid assumption. As noted by Pickhardt an assessment of the overall cost effectiveness of extracolonic evaluation would require a detailed longitudinal analysis of the long term clinical outcomes and potential benefit derived from early detection of a wide variety of detectable extracolonic disease (72). Given that further studies are needed to answer this question, we have focused the discussion below on the prevalence of the extracolonic findings and the costs associated with evaluating these findings.

There is a wide range in definitions and classifications of extracolonic lesions, the procedures for reporting extracolonic lesions, and the recommendations for further work-up of such lesions. The overall rates of any extracolonic lesions have ranged from 27% (107) to 69% (108) in a screening population. The prevalence of clinically significant extracolonic findings is generally lower with a range from 4.5% in the Department of Defense study (30) to 16% in the National

CT Colonography Trial (31). The definition of clinically significant findings has varied across studies but in general use meant a finding which should result in a referral for further evaluation. In several studies (107-109) the cost for the extracolonic assessment is only those costs for additional radiological evaluation. These costs for additional radiological evaluation are averaged across all with CT colonography screening; average costs range from \$24 to \$34 per patient screened. These average costs reflect both the percent with clinically significant findings detected, as well as the percent of patients who received further radiological work-up of the total number screened. Additional costs due to surgical or medical evaluation and treatment, laboratory evaluations, and longer term medical surveillance for these conditions were not included. In 2008 Pickhardt (72) reported that the average surgical and inpatient hospital costs (\$67.54) per patient screened by CT colonography were higher than the non-surgical (\$31.02) costs of evaluating unknown extracolonic findings of at least moderate potential clinical importance in a prospectively screening CT cohort. (Further medical evaluation and surveillance was not included in these costs.) Clear guidance is needed in what findings should be considered as clinically important. Xiong (110) and Kimberly (111) reported the evaluation of extracolonic findings in cohorts in which all extracolonic findings were reported to the primary care physicians without guidance as to what findings required further evaluation. Average cost for evaluating the extracolonic was \$248 per patient screened for the Kimberly cohort and £153 (in 2006) for Xiang's cohort. Both studies included costs from clinic visits, imaging and laboratory studies, and medical procedures that were generated as a result of detection of extracolonic findings at CT colonography screening. In the Kimberly cohort 18% had clinically important extracolonic findings but 24% of patients screened had further evaluation. The average cost across all with CT colonography screening was \$185 for additional radiographic imaging, \$8 for laboratory studies, and \$38 for medical procedures. In the Xiong cohort 52% had at least 1 extracolonic finding; 11% of all screened had further evaluation; 87% of the total costs for evaluation were generated by surgical treatments and their sequelae. (General Practice consultation fees were not included in the costs.) These results represent the wide variation in classification of extracolonic findings reported for evaluation, the range of costs ascertained by the different studies, and the time periods of evaluating subsequent medical management initiated from the initial notification of extracolonic findings.

Pickhardt (73) notes that there are clinical and ethical concerns in withholding or not reviewing imaged regions and advocates for responsible management of further evaluation of extracolonic findings. In 2005 the Working Group on Virtual Colonoscopy of the American College of Radiology Colon Cancer committee developed a quality assessment tool for CT colonography which includes a classification system for extracolonic with recommendations for further evaluation of those which could be clinically important (86). E0 findings are those from a limited exam; E1 a normal examination; E2 clinically unimportant finding; E3 likely unimportant finding, incompletely characterized, but work-up may be indicated and E4, potentially important finding; which should be communicated to the referring physician. Prior to this classification the definition of the extracolonic findings and the severity level of triggering referral for work up has varied. This system, if universally adopted, may help to ensure that referrals for evaluation of extracolonic lesions are done more consistently and appropriately.

The US Preventive Services Task Force found that thus far there is insufficient evidence to determine whether there is net benefit or net harm to evaluation of extracolonic findings and has

stated this lack of evidence as a reason for not recommending CT colonography as a screening test for the average risk population (17). A thorough assessment of this issue will require long-term follow-up of a screening cohort with assessment of the prevalence, follow-up, treatment for extracolonic findings and any attenuate complications. Such a study will need to include all medical costs from radiology, surgery, laboratory, drugs, or other associated medical activities to evaluate and treat conditions uncovered as extracolonic findings. There is not sufficient evidence in this format in the literature. In this report we presented a summary of the prevalence of extracolonic findings in screening and in symptomatic cohorts and the costs incurred in evaluation. A fuller assessment is beyond the scope of this report.

### Consistency of Results from Three Microsimulation Models

All analyses were conducted by three separate microsimulation modeling groups of the National Cancer Institute-sponsored modeling consortium, CISNET, using independently developed models but with common inputs. The comparability of the findings of the three modeling groups strengthens the credibility of our results and can be viewed as a sensitivity analysis on the underlying natural history assumptions. The three models were independently developed prior to performing the cost effectiveness analyses presented here. All three models have been calibrated to CRC incidence rates from a pre-screening era. All the models have been extensively validated against clinical trial data on Hemocult II screening. The models do differ in the dwell time from adenoma to clinically detectable CRC. The MISCAN model assumes a shorter dwell time compared with the SimCRC and CRC-SPIN models. Based on this difference in dwell time, the MISCAN model estimates fewer life-years saved from removing adenomas as a result of screening than the SimCRC and CRC-SPIN models, and estimates a greater benefit for shorter rescreening intervals for adenoma-sensitive tests than does the other two models. The fact that all three models come to similar conclusions with respect to cost-effectiveness and threshold costs of CT colonography screening shows the robustness of the results for uncertainties in the duration of the adenoma-carcinoma sequence.

The distribution of dwell time from adenoma to carcinoma is not known with certainty. The uncertainty on dwell time affects the assessment of all the screening tests, including CT colonography. In particular it affects the tests with respect to detection of adenomas.

The microsimulation models are well situated to address the comparison of CT colonography to other colorectal cancer screening strategies in relationship to differences in sensitivity by size of adenomas and of colorectal cancer, the impact of varying lesion size cut points for referral on to optical colonoscopy, varying the years before CT colonography rescreening and deferential differences in adherence. The microsimulation modeling results also reflect a program of systematic screening, surveillance, and treatment from ages 65 to 80 with follow-up until age 100 of all in the cohort. Thus programmatic effects are ascertained over time.

### Other Cost-effectiveness Analyses

Several other studies have been published on the cost-effectiveness of CT colonography screening in the general population (**Table 15**). In all these studies, the threshold costs for CT colonography screening were higher than the 25-40% of colonoscopy costs found in this study. An important reason for this is that we compared CT colonography screening with all other available test strategies, whereas most other studies compared CT colonography only to

colonoscopy, sigmoidoscopy or Hemoccult II. None of the other cost-effective analyses included the improved Hemoccult SENSA or fecal immunochemical testing strategies as a comparator. Sonnenberg estimated that 10-yearly intensive CT colonography should cost 46% of colonoscopy costs to have the same costs per life-year gained (112). The estimated threshold costs from Ladabaum were slightly higher (60%), but he assumed better CT colonography test sensitivity (113). Comparing 10-yearly CT colonography with 10-yearly colonoscopy in our study yielded threshold costs of 49-71% of colonoscopy costs (**Appendix 4**), but we had a referral threshold of 6 mm instead of 0 mm. Vijan compared CT colonography every 5 years (referral of all lesions) with 10-yearly colonoscopy(114). They found threshold costs of 75% of colonoscopy costs. A similar comparison, but with a 6 mm threshold in our study, yields costs of 39-44% (**Appendix 4**). This is explained by better specificity in Vijan’s assumptions. Using the performance characteristics of 2D CT colonography (which had lower sensitivity than in this analysis, but still better specificity), Vijan found very low CT colonography threshold costs. Finally, Pickhardt compared 10-yearly CT colonography screening with a referral threshold of 6 mm to 10-yearly colonoscopy screening (42). He found that with CT colonography costs at 70% of colonoscopy costs, CT colonography screening with referral of lesions 6 mm and larger was cost-effective compared to colonoscopy. This is somewhat higher than the estimate from the same comparison in our study (49-71%).

Recent cost-effectiveness analyses include Landsorp-Vogelaar (115) and the Canadian Agency for Drugs and Technologies in Health (116) with similar findings that CT colonography is dominated by optical colonoscopy.

**Table 15:** Literature overview of US studies estimating the cost-effectiveness of CT colonography screening in the average-risk population

Study	Comparator strategy	Sensitivity CTC for adenomas	Specificity CTC	Threshold costs as % of colonoscopy costs
Sonnenberg 1999	10-yearly colonoscopy	80%	95%	46% for 10-yearly CTC, referral 0 mm
Ladabaum 2004	10-yearly colonoscopy	Small: 87% Medium: 87% Large: 94%	85%	60% for 10-yearly CTC, referral 0 mm
Vijan 2007	10-yearly colonoscopy	Small: 46% Medium: 83% Large: 91%	91%	75% for 5-yearly CTC, referral 0 mm
Pickhardt 2007	10-yearly colonoscopy	Small: 48% Medium: 70% Large: 85%	86%	>70% for 10-yearly CTC, referral 6 mm

CTC: CT-colonography

#### Limitations of Modeling Assumptions

The models simulate the progression from adenoma to CRC by increasing the size of the adenomas over time. Because adenoma size, villous component, and high-grade dysplasia are highly correlated (88), the size representation indirectly represents histology and high grade.

However, the models do not separately simulate the step from adenoma with low-grade dysplasia to an adenoma with high-grade dysplasia. We also did not allow for de novo cancers (cancers that arise without a prior adenoma state). Lastly, we assumed that SEER incidence data prior to the time of active CRC screening in the US is a good representation of the cancer incidence expected today in an unscreened population. However, because there has been a small net improvement in CRC lifestyle risk factors for CRC over time (46, 61), estimates of CRC incidence may be overestimated. The impact of overestimating CRC incidence is that all CRC screening benefits are also overestimated, though we would not expect significant differences in the relative benefit across strategies.

In the current analysis, we assumed conditional independence of repeat screenings. Consequently we assumed that there were no systematic false-negative results for adenomas and cancers. This is likely a reasonable assumption for FOBT and fecal immunochemical testing because bleeding of a lesion is assumed to be a random event, so that if a test misses a lesion the first time, then it has approximately the same probability of catching a bleed on the next screen. This assumption may be less reasonable for optical endoscopy, as certain lesions may be more difficult to find (e.g., in a fold) but is a reasonable assumption for CT colonography which can detect lesions on folds (117).

In this analysis, we included the current recommendations for average-risk CRC screening as the comparator strategies. We did not consider alternative screening intervals for the currently recommended screening tests. We also made the assumptions that screening would stop at age 80 and that individuals would remain on a surveillance schedule for their lifetime, which may not be realistic assumptions for what occurs in practice.

We did not use quality adjusted life years gained because we did not have good measures on the effects of screening on quality of life particularly as quality relates to the anxiety of waiting.

In our sensitivity analysis of screening adherence we assumed that individuals would be either fully adherent with a screening strategy or never screened. This is an oversimplification of what occurs in practice, but is closer to reality than an assumption that individuals show up randomly to their scheduled screens. A study by Coups et al. (118) of data from the 2000 National Health Interview Survey found that those who were not adherent to colorectal cancer screening were less likely to have a regular source of care and less likely to have visited a general practitioner in the previous 12 months and had more risk factors for colorectal cancer than those who were adherent.

#### Limitations of Cost Estimates

The costs of the screening tests, as well as the costs of complications associated with screening (primarily colonoscopy), were based on 2007 Medicare payment rates. To the extent that these rates change differentially in the future (e.g., a decrease in the payment rate for colonoscopy) our results will change.

Costs for CRC treatment were for the period 1998 to 2003. In this period use of the expensive biological therapies cetuximab and bevacizumab was limited (119). We would expect that inclusion of these costs as later data become available would make the cost-effectiveness more

favorable overall. CRC screening can have two potentially beneficial effects: 1) primary prevention of CRC through detection and removal of adenomas that might have eventually become cancer, and 2) early detection of CRC, when it is in an earlier stage that is more amenable to treatment. In general, those strategies that are associated with a higher reduction in cancer incidence (i.e., act largely through primary prevention rather than early detection) will have a greater net savings.

With the exception of Warren, Klabunde, and Brown upcoming manuscript (78), there are few data specifically on colonoscopy complications in the Medicare population. For example, the Warren analysis reports hospitalization for dehydration following colonoscopy. This complication was not cited in the general population studies across ages. Complications rates are generally lower in organized screening programs, which often focus on the age group of 50 to 65 for CRC screening. Consequently a program to track complications in Medicare beneficiaries who receive CRC screening would be of value to assess the magnitude of risk for this age group.

## **CONCLUSIONS**

The results of this cost-effectiveness analysis suggest that CT colonography does provide a benefit in terms of life-years gained compared with no screening but the cost, relative to the benefit derived and to the availability and costs of other CRC tests (such as colonoscopy without polypectomy at \$500), would need to be in range of \$108 to \$205 to be a non-dominated strategy, provided that the estimates of sensitivity and specificity as stated in the Department of Defense study (30) and National CT Colonography trial (31) are obtained in community-based screening settings. Our findings are based on the analysis of an unscreened 65-year-old cohort using a payer perspective under the assumption of a 5-yearly screening interval for CT colonography with referral to colonoscopy for 6 mm lesions or larger. Threshold costs are similar for a 50-year old cohort (range of \$72 to \$179) but can be somewhat higher when the analysis is performed using a modified societal perspective (\$154 to \$336), though these costs include beneficiary costs and time costs.

There is great potential for CT colonography as a CRC screening test in an average-risk population, especially if adherence for CT colonography is differentially higher than that of other CRC screening tests or costs less than colonoscopy. CT colonography is a rapidly evolving technology; new techniques must be evaluated in average risk population and the radiation risks and benefit of detection of extracolonic findings determined.

## REFERENCES

1. Cancer Facts and Figures American Cancer Society, Available at: <http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf>; 2008.
2. **Ries LAG, Melbert D, Krapcho M, et al.** SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, <http://seer.cancer.gov/csr/1975-2004/>, based on November 2006 SEER data submission, posted to the SEER website, 2007; 2004.
3. **Morson BC.** The pathogenesis of colorectal cancer. Introduction. *Major Probl Pathol.* 1978;10:1-13.
4. **Mandel J, Bond J, Church T, et al.** Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. *N Engl J Med.* 1993;328(19):1365-71.
5. **Mandel JS, Church TR, Ederer F, Bond JH.** Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. *J Natl Cancer Inst.* 1999;91(5):434-7.
6. **Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O.** Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet.* 1996;348(9040):1467-71.
7. **Hardcastle JD, Chamberlain JO, Robinson MH, et al.** Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet.* 1996;348(9040):1472-7.
8. **Mandel JS, Church TR, Bond JH, et al.** The effect of fecal occult-blood screening on the incidence of colorectal cancer. *N Engl J Med.* 2000;343(22):1603-7.
9. **Winawer SJ, Zauber AG, Ho MN, et al.** Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. *N Engl J Med.* 1993;329(27):1977-81.
10. **Selby JV, Friedman GD, Quesenberry CP, Jr., Weiss NS.** A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. *N Engl J Med.* 1992;326(10):653-7.
11. **Atkin WS, Edwards R, Wardle J, et al.** Design of a multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer screening. *J Med Screen.* 2001;8(3):137-44.
12. **Segnan N, Senore C, Andreoni B, et al.** Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE. *J Natl Cancer Inst.* 2002;94(23):1763-72.
13. **Prorok PC, Andriole GL, Bresalier RS, et al.** Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Control Clin Trials.* 2000;21(6 Suppl):273S-309S.
14. **Shapiro JA, Seeff LC, Thompson TD, Nadel MR, Klabunde CN, Vernon SW.** Colorectal cancer test use from the 2005 National Health Interview Survey. *Cancer Epidemiol Biomarkers Prev.* 2008;17(7):1623-30.
15. **U.S. Preventive Services Task Force.** Screening for colorectal cancer: recommendation and rationale. *Ann Intern Med.* 2002;137(2):129-31.
16. **Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN.** Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2002;137(2):132-41.
17. Screening for colorectal cancer: u.s. Preventive services task force recommendation statement. *Ann Intern Med.* 2008;149(9):627-37.

18. **Winawer SJ, Fletcher RH, Miller L, et al.** Colorectal cancer screening: clinical guidelines and rationale. *Gastroenterology*. 1997;112(2):594-642.
19. **Winawer S, Fletcher R, Rex D, et al.** Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. *Gastroenterology*. 2003;124(2):544-60.
20. **Winawer SJ, Zauber AG, Fletcher RH, et al.** Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Published jointly in *Gastroenterology* 2006;130:1872-85 and *CA Cancer J Clin* 2006;56:143-59. 2006.
21. **Levin B, Lieberman DA, McFarland B, et al.** Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Published jointly in *Gastroenterology*. May 2008;134(5):1570-1595, *CA Cancer J Clin* 2008;58(3):130-160, and *Radiology* 2008.
22. **Smith RA, Cokkinides V, Eyre HJ.** American Cancer Society guidelines for the early detection of cancer, 2006. *CA Cancer J Clin*. 2006;56(1):11-25; quiz 49-50.
23. **Zauber AG, Lansdorf-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM.** Evaluating test strategies for colorectal cancer screening: a decision analysis for the u.s. Preventive services task force. *Ann Intern Med*. 2008;149(9):659-69.
24. **van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML.** Report to the Agency for Healthcare Research and Quality: a comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. August 2003. Accessed January 11, 2009 <http://www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&id=20>. 2003.
25. **Zauber AG, Lansdorf-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM.** Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. Available from: <https://www.cms.hhs.gov/mcd/viewtechassess.asp?from2=viewtechassess.asp&id=212&>. 2007.
26. **Vining DJ, Gelfand DW, Bechtold RE, Grishaw EKSRY.** Technical feasibility of colon imaging with helical CT and virtual reality (abstr). *AJR Am J Roentgenol*. 1994;162((Suppl)):104.
27. **Zauber AG, Levin TR, Jaffe CC, Galen BA, Ransohoff DF, Brown ML.** Implications of new colorectal cancer screening technologies for primary care practice. *Med Care*. 2008;46(9 Suppl 1):S138-46.
28. **McFarland EG, Levin B, Lieberman DA, et al.** Revised colorectal screening guidelines: joint effort of the American Cancer Society, U.S. Multisociety Task Force on Colorectal Cancer, and American College of Radiology. *Radiology*. 2008;248(3):717-20.
29. **Blue Cross Blue Shield Association.** CT Colonography (“Virtual Colonoscopy”) for Colon Cancer Screening.: Executive Summary. Vol. 2008; 2008. <http://www.bcbs.com/blueresources/tec> accessed January 11, 2009
30. **Pickhardt PJ, Choi JR, Hwang I, et al.** Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. *N Engl J Med*. 2003;349(23):2191-200.

31. **Johnson CD, Chen MH, Toledano AY, et al.** Accuracy of CT colonography for detection of large adenomas and cancers. *N Engl J Med.* 2008;359(12):1207-17.
32. **Fenlon HM, Nunes DP, Schroy PC, 3rd, Barish MA, Clarke PD, Ferrucci JT.** A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps. *N Engl J Med.* 1999;341(20):1496-503.
33. **Yee J, Akerkar GA, Hung RK, Steinauer-Gebauer AM, Wall SD, McQuaid KR.** Colorectal neoplasia: performance characteristics of CT colonography for detection in 300 patients. *Radiology.* 2001;219(3):685-92.
34. **Johnson CD, Harmsen WS, Wilson LA, et al.** Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps. *Gastroenterology.* 2003;125(2):311-9.
35. **Cotton PB, Durkalski VL, Pineau BC, et al.** Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. *JAMA.* 2004;291(14):1713-9.
36. **Rockey DC, Paulson E, Niedzwiecki D, et al.** Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. *Lancet.* 2005;365(9456):305-11.
37. **Mulhall BP, Veerappan GR, Jackson JL.** Meta-analysis: computed tomographic colonography. *Ann Intern Med.* 2005;142(8):635-50.
38. **Whitlock EP, Lin JS, Liles E, Beil TL, Fu R.** Screening for colorectal cancer: a targeted, updated systematic review for the u.s. Preventive services task force. *Ann Intern Med.* 2008;149(9):638-58.
39. **Whitlock EP, Lin J, Liles E, et al.** Screening for colorectal cancer: an updated systematic review. *Rockville, MD: Agency for Healthcare Research and Quality.* Vol. 2008; 2008.
40. **Johnson CD, Fletcher JG, MacCarty RL, et al.** Effect of slice thickness and primary 2D versus 3D virtual dissection on colorectal lesion detection at CT colonography in 452 asymptomatic adults. *AJR Am J Roentgenol.* 2007;189(3):672-80.
41. **Kim SH, Lee JM, Eun HW, et al.** Two- versus three-dimensional colon evaluation with recently developed virtual dissection software for CT colonography. *Radiology.* 2007;244(3):852-64.
42. **Pickhardt PJ, Lee AD, Taylor AJ, et al.** Primary 2D versus primary 3D polyp detection at screening CT colonography. *AJR Am J Roentgenol.* 2007;189(6):1451-6.
43. **Loeve F, Boer R, van Oortmarsen GJ, van Ballegooijen M, Habbema JDF.** The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. *Comput Biomed Res.* 1999;32:13-33.
44. **Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarsen GJ, Habbema JD.** Endoscopic colorectal cancer screening: a cost-saving analysis. *J Natl Cancer Inst.* 2000;92(7):557-63.
45. **Frazier AL, Colditz GA, Fuchs CS, Kuntz KM.** Cost-effectiveness of screening for colorectal cancer in the general population. *Jama.* 2000;284(15):1954-61.
46. **Knudsen AB.** Explaining secular trends in colorectal cancer incidence and mortality with an empirically-calibrated microsimulation model. Harvard University; 2005:183 pages.
47. **Clark JC, Collan Y, Eide TJ, et al.** Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. *Int J Cancer.* 1985;36(2):179-86.

48. **Blatt LJ.** Polyps of the colon and rectum: incidence and distribution. *Dis Colon Rectum.* 1961;4:277-282.
49. **Arminski TC, McLean DW.** Incidence and distribution of adenomatous polyps of the colon and rectum based on 1.000 autopsy examinations. *Dis Colon Rectum.* 1964;7:249-61.
50. **Vatn MH, Stalsberg H.** The prevalence of polyps of the large intestine in Oslo: an autopsy study. *Cancer.* 1982;49(4):819-25.
51. **Jass JR, Young PJ, Robinson EM.** Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. *Gut.* 1992;33:1508-1514.
52. **Johannsen LG, Momsen O, Jacobsen NO.** Polyps of the large intestine in Aarhus, Denmark. An autopsy study. *Scand J Gastroenterol.* 1989;24(7):799-806.
53. **Bombi JA.** Polyps of the colon in Barcelona, Spain. *Cancer.* 1988;61(7):1472-1476.
54. **Williams AR, Balasooriya BA, Day DW.** Polyps and cancer of the large bowel: a necropsy study in Liverpool. *Gut.* 1982;23(10):835-42.
55. **Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM.** Adenomatous lesions of the large bowel. *Cancer.* 1979;43:1847-1857.
56. **Chapman I.** Adenomatous polypi of large intestine: incidence and distribution. *Ann Surg.* 1963;157:223-226.
57. **Rutter CM, Yu O, Miglioretti DL.** A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. *Stat Med.* 2007;26(1):98-109.
58. **Doria-Rose VP, Levin TR, Selby JV, Newcomb PA, Richert-Boe KE, Weiss NS.** The incidence of colorectal cancer following a negative screening sigmoidoscopy: implications for screening interval. *Gastroenterology.* 2004;127(3):714-22.
59. Surveillance Epidemiology, and End Results (SEER) Program (<http://www.seer.cancer.gov>) SEER\* Stat Database: Incidence - SEER 9 Regs Public-Use, Nov2003 Sub (1973-2001), National Cancer Institute. DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission.
60. **Vogelaar I, van Ballegooijen M, Schrag D, et al.** How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. *Cancer.* 2006;107(7):1624-33.
61. **Knudsen AB, Wang YC, Weinstein MC, Weeks JC, Kuntz KM.** Explaining the secular trends in colorectal cancer incidence and mortality using a population-based microsimulation model [Abstract]. *Med Decis Making.* 2004;24.
62. **Gold MR, Siegel JE, Russell LB, Weinstein MC.** *Cost-Effectiveness in Health and Medicine* New York (NY): Oxford University Press; 1996.
63. **Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y.** A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. *Gastroenterology.* 2005;129(2):422-8.
64. **Morikawa T, Kato J, Yamaji Y, et al.** Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. *Am J Gastroenterol.* 2007;102(10):2259-64.
65. **Allison JE, Sakoda LC, Levin TR, et al.** Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. *J Natl Cancer Inst.* 2007;99(19):1462-70.

66. **Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME.** Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. *N Engl J Med.* 2004;351(26):2704-14.
67. **Ahlquist DA, Sargent DJ, Loprinzi CL, et al.** Stool DNA and occult blood testing for screen detection of colorectal neoplasia. *Ann Intern Med.* 2008;149(7):441-50, W81.
68. **Gyrd-Hansen D, Sogaard J, Kronborg O.** Analysis of screening data: colorectal cancer. *Int J Epidemiol.* 1997;26(6):1172-81.
69. **Eide TJ, Stalsberg H.** Polyps of the large intestine in Northern Norway. *Cancer.* 1978;42:2839-2848.
70. **Adam I, Ali Z, Shorthouse A.** How accurate is the endoscopist's assessment of visualization of the left colon seen at flexible sigmoidoscopy? *Colorectal Dis.* Vol. 2; 2001.
71. **van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E.** Polyp miss rate determined by tandem colonoscopy: a systematic review. *Am J Gastroenterol.* 2006;101(2):343-50.
72. **Pickhardt PJ, Hanson ME, Vanness DJ, et al.** Unsuspected extracolonic findings at screening CT colonography: clinical and economic impact. *Radiology.* 2008;249(1):151-9.
73. **Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G.** Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. *N Engl J Med.* 2000;343(3):162-8.
74. **Regula J, Rupinski M, Kraszewska E, et al.** Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. *N Engl J Med.* 2006;355(18):1863-72.
75. **Pox C, Schmiegel W, Classen M.** Current status of screening colonoscopy in Europe and in the United States. *Endoscopy.* 2007;39(2):168-73.
76. **Levin TR, Conell C, Shapiro JA, Chazan SG, Nadel MR, Selby JV.** Complications of screening flexible sigmoidoscopy. *Gastroenterology.* 2002;123(6):1786-92.
77. **Levin TR, Zhao W, Conell C, et al.** Complications of colonoscopy in an integrated health care delivery system. *Ann Intern Med.* 2006;145(12):880-6.
78. **Klabunde CN, Warren JL, Ransohoff DF, Brown ML.** Complications of colonoscopy in the Medicare population. *Gastroenterology.* 2007;132:Supplement 2 A149 (995).
79. **Pickhardt PJ.** Incidence of colonic perforation at CT colonography: review of existing data and implications for screening of asymptomatic adults. *Radiology.* 2006;239(2):313-6.
80. **Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI.** Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. *J Natl Cancer Inst.* 2003;95(3):230-6.
81. **Tran DQ, Rosen L, Kim R, Riether RD, Stasik JJ, Khubchandani IT.** Actual colonoscopy: what are the risks of perforation? *Am Surg.* 2001;67(9):845-7; discussion 847-8.
82. **Rabeneck L, Paszat LF, Hilsden RJ, et al.** Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. *Gastroenterology.* 2008;135(6):1899-1906, 1906 e1.
83. **Yabroff KR, Lamont EB, Mariotto A, et al.** Cost of care for elderly cancer patients in the United States. *J Natl Cancer Inst.* 2008;100(9):630-41.

84. **Jonas DE, Russell LB, Sandler RS, Chou J, Pignone M.** Patient time requirements for screening colonoscopy. *Am J Gastroenterol.* 2007;102(11):2401-10.
85. **Yabroff KR, Davis WW, Lamont EB, et al.** Patient time costs associated with cancer care. *J Natl Cancer Inst.* 2007;99(1):14-23.
86. **Zalis ME, Barish MA, Choi JR, et al.** CT colonography reporting and data system: a consensus proposal. *Radiology.* 2005;236(1):3-9.
87. **Butterly LF, Chase MP, Pohl H, Fiarman GS.** Prevalence of clinically important histology in small adenomas. *Clin Gastroenterol Hepatol.* 2006;4(3):343-8.
88. **O'Brien MJ, Winawer SJ, Zauber AG, et al.** The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. *Gastroenterology.* 1990;98(2):371-9.
89. **Soetikno RM, Kaltenbach T, Rouse RV, et al.** Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. *Jama.* 2008;299(9):1027-35.
90. **Lieberman D.** Nonpolypoid colorectal neoplasia in the United States: the parachute is open. *Jama.* 2008;299(9):1068-9.
91. **Fidler JL, Johnson CD, MacCarty RL, Welch TJ, Hara AK, Harmsen WS.** Detection of flat lesions in the colon with CT colonography. *Abdom Imaging.* 2002;27(3):292-300.
92. **Park SH, Lee SS, Choi EK, et al.** Flat colorectal neoplasms: definition, importance, and visualization on CT colonography. *AJR Am J Roentgenol.* 2007;188(4):953-9.
93. **O'Brien MJ, Winawer SJ, Zauber AG.** Flat Adenomas in the National Polyp Study (NPS) are not associated with an increased risk of high grade dysplasia initially nor during surveillance. *Clinical Gastroenterology and Hepatology 2004.* 2004;2:905-911.
94. **Pickhardt PJ, Taylor AJ, Kim DH, Reichelderfer M, Gopal DV, Pfau PR.** Screening for colorectal neoplasia with CT colonography: initial experience from the 1st year of coverage by third-party payers. *Radiology.* 2006;241(2):417-25.
95. **Callstrom MR, Johnson CD, Fletcher JG, et al.** CT colonography without cathartic preparation: feasibility study. *Radiology.* 2001;219(3):693-8.
96. **Iannaccone R, Laghi A, Catalano C, et al.** Computed tomographic colonography without cathartic preparation for the detection of colorectal polyps. *Gastroenterology.* 2004;127(5):1300-11.
97. **Pickhardt PJ.** Colonic preparation for computed tomographic colonography: understanding the relative advantages and disadvantages of a noncathartic approach. *Mayo Clin Proc.* 2007;82(6):659-61.
98. **Brenner DJ, Hall EJ.** Computed tomography--an increasing source of radiation exposure. *N Engl J Med.* 2007;357(22):2277-84.
99. **Mettler FA, Jr., Thomadsen BR, Bhargavan M, et al.** Medical radiation exposure in the U.S. in 2006: preliminary results. *Health Phys.* 2008;95(5):502-7.
100. **Gluecker TM, Johnson CD, Harmsen WS, et al.** Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences. *Radiology.* 2003;227(2):378-84.
101. **Bosworth HB, Rockey DC, Paulson EK, et al.** Prospective comparison of patient experience with colon imaging tests. *Am J Med.* 2006;119(9):791-9.

102. **Schwartz DC, Dasher KJ, Said A, et al.** Impact of a CT colonography screening program on endoscopic colonoscopy in clinical practice. *Am J Gastroenterol.* 2008;103(2):346-51.
103. **Brenner DJ, Georgsson MA.** Mass screening with CT colonography: should the radiation exposure be of concern? *Gastroenterology.* 2005;129(1):328-37.
104. **Fletcher RH, Pignone M.** Extracolonic findings with computed tomographic colonography: asset or liability? *Arch Intern Med.* 2008;168(7):685-6.
105. **Hassan C, Pickhardt PJ, Laghi A, et al.** Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: model simulation with cost-effectiveness analysis. *Arch Intern Med.* 2008;168(7):696-705.
106. **U.S. Preventive Services Task Force.** Screening: Abdominal Aortic Aneurysm. *Ann Intern Med.* 2005;142(3):I52.
107. **Chin M, Mendelson R, Edwards J, Foster N, Forbes G.** Computed tomographic colonography: prevalence, nature, and clinical significance of extracolonic findings in a community screening program. *Am J Gastroenterol.* 2005;100(12):2771-6.
108. **Gluecker TM, Johnson CD, Wilson LA, et al.** Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population. *Gastroenterology.* 2003;124(4):911-6.
109. **Yee J, Kumar NN, Godara S, et al.** Extracolonic abnormalities discovered incidentally at CT colonography in a male population. *Radiology.* 2005;236(2):519-26.
110. **Xiong T, McEvoy K, Morton DG, Halligan S, Lilford RJ.** Resources and costs associated with incidental extracolonic findings from CT colonography: a study in a symptomatic population. *Br J Radiol.* 2006;79(948):948-61.
111. **Kimberly JR, Phillips KC, Santago P, et al.** Extracolonic Findings at Virtual Colonoscopy: An Important Consideration in Asymptomatic Colorectal Cancer Screening. *J Gen Intern Med.* 2008.
112. **Sonnenberg A, Delco F, Bauerfeind P.** Is virtual colonoscopy a cost-effective option to screen for colorectal cancer? *Am J Gastroenterol.* 1999;94(8):2268-74.
113. **Ladabaum U, Song K, Fendrick AM.** Colorectal neoplasia screening with virtual colonoscopy: when, at what cost, and with what national impact? *Clin Gastroenterol Hepatol.* 2004;2(7):554-63.
114. **Vijan S, Hwang I, Inadomi J, et al.** The cost-effectiveness of CT colonography in screening for colorectal neoplasia. *Am J Gastroenterol.* 2007;102(2):380-90.
115. **Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD.** At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. *Int J Cancer.* 2008;124(5):1161-1168.
116. **Ho C, Heitman S, Membe S, et al.** (Agency for Drugs and Technologies in Health). Computed tomographic colonography for colorectal cancer screening in an average risk population: Systematic review and economic evaluation. 2008.
117. **Pickhardt PJ, Nugent PA, Mysliwiec PA, Choi JR, Schindler WR.** Location of adenomas missed by optical colonoscopy. *Ann Intern Med.* 2004;141(5):352-9.
118. **Coups EJ, Manne SL, Meropol NJ, Weinberg DS.** Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. *Cancer Epidemiol Biomarkers Prev.* 2007;16(3):510-6.
119. **Schrag D.** The price tag on progress--chemotherapy for colorectal cancer. *N Engl J Med.* 2004;351(4):317-9.

## **APPENDICES**

1. Model descriptions: (a) MISCAN, (b) SimCRC, (c) CRC-SPIN
2. Comparison of outcomes from the natural history component of the models
3. Additional outcomes of the analyses: Average Cost-Effectiveness Ratios (ACER)
4. Results for the secondary threshold analyses
5. Results for analyses of 50-year-old cohort
6. Derivation of costs per screening test by point of service

## Appendix 1: Model descriptions

*Microsimulation models.* The MISCAN, SimCRC, and CRC-SPIN models from the National Cancer Institute CISNET consortium were used to address the question of the cost-effectiveness of screening with CT colonography. The models used common inputs and assumptions concerning the screening tests but use their independently developed natural history models in addressing these questions.

### Appendix 1a. Description of the MISCAN-COLON model for natural history and intervention

#### *MISCAN Model overview*

MISCAN-COLON is a semi-Markov microsimulation program to simulate the effect of screening and other interventions on colorectal cancer (CRC) incidence and mortality. With microsimulation we mean that each individual in the population is simulated separately. The model is semi-Markov in the sense that:

- distributions other than exponential are possible in each disease state
- transitions in one state can depend on transitions in earlier states,
- transitions can be age and calendar time dependent

All events in the model are discrete, but the durations in each state are continuous. Hence, there are no annual transitions in the model.

The development of CRC in the model is assumed to occur according to the adenoma carcinoma sequence. This means that adenomas arise in the population, some of which eventually develop into CRC. We assume that there are two types of adenomas: progressive and non-progressive adenomas. Non-progressive adenomas can grow in size, but will never develop into a cancer. Progressive adenomas have the potential to develop into cancer, if the person in whom the adenoma develops lives long enough.

All adenomas start as a small (1-5 mm) adenoma. They can grow in size to medium (6-9 mm) and large (10+ mm) adenoma. Progressive medium and large adenomas can transform into a malignant cancer stage I, not yet giving symptoms (preclinical cancer). The cancer then progresses from stage I (localized) eventually to stage IV (distant metastasis). In each stage there is a probability of the cancer giving symptoms and being clinically detected. The time between the onset of a progressive adenoma and the clinical detection of CRC is assumed to be on average 20 years. After clinical detection a person can die of CRC, or of other causes based on the survival rate. The survival from CRC is highly dependent on the stage in which the cancer was detected.

#### *MISCAN Simulation of an individual*

Figure 2a shows how the model generates an individual life history. First MISCAN-COLON generates a time of birth and a time of death of other causes than CRC for an individual. This is shown in the top line of figure 1a. This line constitutes the life history in the absence of CRC. Subsequently, MISCAN-COLON generates adenomas for an individual. For most individuals no adenomas are simulated, for some multiple. In this example MISCAN-Colon has generated two adenomas for the individual. The first adenoma occurs at a certain age and grows in size from





## Appendix 1b. Description of the SimCRC model for natural history and intervention model

### SimCRC Model

*SimCRC overview.* The SimCRC model of CRC was developed to evaluate the impact of past and future interventions on CRC incidence and mortality in the U.S. The model is population-based, meaning that it simulates the life histories of multiple cohorts of individuals of a given year of birth. These cohorts can be aggregated to yield a full cross-section of the population in a given calendar year. For this analysis, we simulated the life histories of only one cohort—those aged 65 years in 2005. SimCRC is a hybrid model, specifically it is a cross between a Markov model and a discrete event simulation. While annual (often age-specific) probabilities define the likelihood of transitioning through a series of health states, the model does not have annual cycles. Instead, the age at which a given transition takes place for each simulated individual is drawn from a cumulative probability function.

*SimCRC simulation of the natural history of CRC.* The SimCRC natural history model describes the progression of underlying colorectal disease (i.e., the adenoma-carcinoma sequence) among an unscreened population. Each simulated individual is assumed to be free of adenomas and CRC at birth. Over time, he is at risk of forming one or more adenomas. Each adenoma may grow in size from small ( $\leq 5$  mm) to medium (6-9 mm) to large ( $\geq 10$  mm). Medium and large adenomas may progress to preclinical CRC, although most will not in an individual's lifetime. Preclinical cancers may progress in stage (I-IV) and may be detected via symptoms, becoming a clinical case. Individuals with CRC may die from their cancer or from other causes.

The SimCRC model allows for heterogeneity in growth and progression rates across multiple adenomas within an individual. While all adenomas have the potential to develop into CRC, most will not. The likelihood of adenoma growth and progression to CRC is allowed to vary by location in the colorectal tract (i.e., proximal colon vs. distal colon vs. rectum).

*SimCRC simulation of screening.* The screening component of the SimCRC model is superimposed on the natural history model. It allows for the detection and removal of adenomas and the diagnosis of preclinical CRC. In a screening year, a person with an underlying (i.e., undiagnosed) adenoma or preclinical cancer faces the chance that the lesion is detected based on the sensitivity of the test for adenomas by size or for cancer and the reach of the test. Individuals who do not have an underlying adenoma or preclinical cancer also face the risk of having a positive screening test (and undergoing unnecessary follow-up procedures) due to the imperfect specificity of the test. While the model does not explicitly simulate non-adenomatous polyps, they are accounted for through the specificity of the test. Additionally, individuals with false-negative screening tests (i.e., individuals with an adenoma or preclinical cancer that was missed by the screening test) may be referred for follow-up due to the detection of non-adenomatous polyps. The model incorporates the risk of fatal and non-fatal complications associated with various screening procedures. It also accounts for the fact that not all individuals are adherent with CRC screening guidelines and that adherence patterns are correlated within an individual.

See the model profiler <http://cisnet.cancer.gov/profiles/> for a more detailed discussion of the transition probabilities for the adenomas and colorectal cancer.

## Appendix 1c. Description of CRC-CPIN model for natural history and intervention

### *Model overview*

For this analysis we will use the ColoRectal Cancer Simulated Population model for Incidence and Natural history (CRC-SPIN). CRC-SPIN is a semi-Markov microsimulation program to simulate the effect of screening and other interventions on colorectal cancer (CRC) incidence and mortality. With microsimulation we mean that each individual in the population is simulated separately. The model is semi-Markov in the sense that:

- distributions other than exponential are possible in each disease state
- transitions can be age, location, and calendar time dependent

All events in the model are discrete, but the durations in each state are continuous. Hence, there are no annual transitions in the model.

The CRC-SPIN model assumes that all colorectal cancers arise from an adenoma and models shifts from adenoma initiation to preclinical and clinically detectable CRC in continuous time using four components, described below. CRC-SPIN does not model adenomas <1mm, and implicitly assume that these are unobservable.

**1. Adenoma Risk:** CRC-SPIN models the occurrence of 1mm adenomas with a non-homogeneous Poisson process. Risk is modeled using a log-linear model. Baseline individual-level log-risk varies across individuals and has a Normal distribution. CRC-SPIN models systematic differences in the log-risk of adenomas for men and women, and by age. Age-effects are modeled using a piecewise linear age effect on log-risk with four age-risk intervals: [20,50), [50,60), [60,70), and (70. Under the CRC-SPIN model, individuals younger than 20 are not at risk of developing 1mm adenomas. Once initiated, adenomas are assigned a location using a multinomial distribution across 6 possible sites of the large intestine (from proximal to distal, with probabilities in parenthesis): 1) cecum (0.08); 2) ascending colon (0.23); 3) transverse colon (0.24); 4) descending colon (0.12); 5) sigmoid colon (0.24); and 6) rectum (0.09).

**2. Adenoma Growth:** CRC-SPIN models adenoma growth as a continuous process. We assume that adenoma growth varies independently across adenomas, both within and between individuals, and we allow different adenoma growth distributions for adenomas in the colon and rectum. The growth model used by CRC-SPIN is asymmetric, with exponential growth early that slows to allow an asymptote at 50mm, the maximum adenoma size. CRC-SPIN simulates adenoma growth by first simulating the time to reach 10mm using a type 2 extreme value distribution, and then solving for growth parameters. The type 2 extreme value distribution has a long right tail but does not heavily weight small values that indicate fast growth.

**3. Transition from Adenoma to Invasive Cancer:** CRC-SPIN models the cumulative probability of adenoma transition up to size  $s$  as a function of location (colon or rectum) and age at adenoma initiation. For an adenoma initiated at age  $a$  in the colon of a man, the probability of transition to preclinical cancer at or before size  $s$  is given by  $c(s,a) = (( [\ln((1cms) + (2cm(a-50)]/3. where (( ) is the standard Normal cumulative distribution function. Cumulative transition probabilities for adenomas in the male rectum, and adenomas in the female colon and rectum have the same form, but with different parameters. For each adenoma, the size at$

transition is independently generated by simulating a Uniform[0,1] pseudodeviate and using an inverse cumulative distribution look-up.

**4. Sojourn Time:** Under the CRC-SPIN model, sojourn time is defined as the time from transition to preclinical cancer to clinical detection, defined as the onset of symptoms leading to detection in the absence of screening. We assume that the sojourn time of each preclinical cancer is independent and has a lognormal distribution that depends on adenoma location (colon or rectum).

**Clinical Outcomes: Stage and Survival:** Once a cancer becomes clinically detectable, CRC-SPIN simulates size and stage at clinical detection. We specify an overall (unconditional) distribution for tumor size at clinical detection using observed SEER size at detection from 1975-1979. We base the conditional distribution of stage given size on estimates from multinomial logistic regression models for the same SEER data. These models include linear and quadratic effects of tumor size on stage at detection. Given cancer size, we determine size during the preclinical period using an exponential model, which assumes a minimum cancer size of 0.5mm and replacement of adenoma cells with cancer cells until the cancer overtakes the adenoma.

Colorectal cancer relative survival probabilities are based on Cox proportional hazards models for relative survival applied to SEER survival data for cases diagnosed from 1975 to 1979, estimated using the CANSURV program (<http://srab.cancer.gov/cansurv/>). Proportional hazards models were stratified by location (colon or rectum) and AJCC stage. Age and sex were included as covariates. Age was treated as continuous, though people 25-34 were grouped with 35 year olds and people 90+ were grouped with 90 year olds due to small cell sizes. Other cause mortality uses survival probabilities based on product-limit estimates for age and birth-year cohorts from the National Center for Health Statistics Databases.

#### *Simulation of screening*

Individual life histories are simulated assuming there is no screening for colorectal cancer. After these life histories are simulated, screening is applied, to allow comparison of events with and without screening. The effectiveness of screening depends on the performance characteristics of the test performed: sensitivity, specificity and reach (for endoscopic tests). In the model, one minus the specificity is defined as the probability of a positive test result in an individual irrespective of any adenomas or cancers present. For a person without any adenomas or cancers, the probability of a positive test result is therefore equal to one minus the specificity. In individuals with adenomas or cancer the probability of a positive test result is dependent on the lack of specificity and the sensitivity of the test for the present lesions. Sensitivity in the model is lesion-specific, where each adenoma or cancer contributes to the probability of a positive test result.

See the model profiler <http://cisnet.cancer.gov/profiles/> for a more detailed discussion of the transition probabilities for the adenomas and colorectal cancer.

**Appendix 2: Comparison of the MISCAN, SimCRC and CRC-SPIN models on natural history outcomes at age 65**

Outcome	MISCAN	SimCRC	CRC-SPIN
Adenoma prevalence, age 65:	39.8%	37.2%	30.7%
Number of adenomas per 1000 by site and size, age 65			
Proximal colon			
≤ 5 mm	121.2	171.7	190.2
6-9 mm	69.9	186.2	67.8
≥ 10 mm	61.8	23.9	40.8
Distal colon			
≤ 5 mm	134.4	124.2	124.5
6-9 mm	77.4	18.2	44.4
≥ 10 mm	68.4	41.6	26.7
Rectum			
≤ 5 mm	133.5	8.7	14.1
6-9 mm	76.8	16.0	9.1
≥ 10 mm	68.1	15.8	20.2
Distribution of adenomas by site and size, age 65 (%)			
Proximal colon			
≤ 5 mm	15	28	35
6-9 mm	9	31	13
≥ 10 mm	8	4	8
Total	31	63	56
Distal colon			
≤ 5 mm	17	20	23
6-9 mm	10	3	8
≥ 10 mm	8	7	5
Total	35	30	36
Rectum			
≤ 5 mm	16	1	3
6-9 mm	9	3	2
≥ 10 mm	8	3	4
Total	34	7	8
CRC incidence among cancer-free 65-year-old population, %			
10-year			
Stage I	0.4	0.4	0.3
Stage II	0.7	0.7	0.7
Stage III	0.5	0.5	0.5
Stage IV	0.5	0.5	0.3
Total	2.1	2.2	1.8

Outcome	MISCAN	SimCRC	CRC-SPIN
CRC incidence among cancer-free 65-year-old population, %			
20-year			
Stage I	0.8	0.8	0.7
Stage II	1.6	1.5	1.4
Stage III	1.0	1.0	1.0
Stage IV	1.0	1.2	0.7
Total	4.4	4.6	3.9
Lifetime			
Stage I	1.0	1.0	0.9
Stage II	2.1	2.0	1.9
Stage III	1.3	1.4	1.4
Stage IV	1.3	1.6	1.0
Total	5.7	6.0	5.3

**Appendix 3: Additional outcomes of the analyses:  
Average Cost-Effectiveness Analysis Ratios (ACER)**

**Table A.3.1.** Discounted costs and discounted life-years gained per 1000 65-year olds and average cost-effectiveness ratios, by CRC screening scenario – MISCAN

Scenario	Discounted Costs, \$	Net Discounted Costs, \$	Discounted LYG	ACER, \$/LYG
No screening	2,714,556	0	0	NA
HII	2,631,879	-82,677	65.7	CS
HS	2,715,683	1,127	81.1	14
FIT	2,777,228	62,672	80.1	782
SIGB	2,823,217	108,661	75.0	1,450
SIG	2,810,249	95,693	76.7	1,247
HII + SIGB	2,790,651	76,095	84.9	896
HII + SIG	2,839,118	124,562	85.4	1,459
HS + SIGB	2,859,815	145,259	88.0	1,651
HS + SIG	2,907,440	192,884	87.9	2,194
FIT + SIGB	3,022,139	307,583	88.1	3,492
FIT + SIG	2,990,860	276,304	88.1	3,137
COL	2,906,228	191,672	86.7	2,211
CTC DoD 3D 6mm 5y	3,469,661	755,106	85.3	8,855
CTC NCTC 2D/3D 6mm 5y	3,489,238	774,683	81.3	9,527

ACER = average cost-effectiveness ratio compared with no screening; LYG = life-years gained compared with no screening; NA = not applicable; CS = cost-saving

**Table A.3.2.** Discounted costs and discounted life-years gained per 1000 65-year olds and average cost-effectiveness ratios, by CRC screening scenario – SimCRC

Scenario	Discounted Costs, \$	Net Discounted Costs, \$	Discounted LYG	ACER, \$/LYG
No screening	2,367,514	0	0	NA
HII	2,082,788	-284,726	59.9	CS
HS	2,042,708	-324,806	81.1	CS
FIT	2,116,618	-250,896	79.8	CS
SIGB	2,168,782	-198,733	65.2	CS
SIG	2,151,925	-215,589	69.1	CS
HII + SIGB	2,085,889	-281,625	85.7	CS
HII + SIG	2,072,929	-294,585	87.0	CS
HS + SIGB	2,151,806	-215,708	92.5	CS
HS + SIG	2,150,786	-216,728	93.0	CS
FIT + SIGB	2,244,313	-123,201	92.3	CS
FIT + SIG	2,244,650	-122,864	92.8	CS
COL	2,173,712	-193,802	93.8	CS
CTC DoD 3D 6mm 5y	2,674,721	307,206	92.0	3,340
CTC NCTC 2D/3D 6mm 5y	2,706,113	338,599	87.2	3,881

ACER = average cost-effectiveness ratio compared with no screening; LYG = life-years gained compared with no screening; NA = not applicable; CS = cost-saving

**Table A.3.3.** Discounted costs and discounted life-years gained per 1000 65-year olds and average cost-effectiveness ratios, by CRC screening scenario – CRC-SPIN

Scenario	Discounted Costs, \$	Net Discounted Costs, \$	Discounted LYG	ACER, \$/LYG
No screening	1,976,803	0	0	NA
HII	1,536,474	-440,329	64.0	CS
HS	1,482,449	-494,354	87.3	CS
FIT	1,574,679	-402,123	84.7	CS
SIGB	1,716,321	-260,482	75.8	CS
SIG	1,626,360	-350,443	80.4	CS
HII + SIGB	1,656,317	-320,486	92.9	CS
HII + SIG	1,590,434	-386,369	94.5	CS
HS + SIGB	1,666,766	-310,037	99.9	CS
HS + SIG	1,611,331	-365,472	100.5	CS
FIT + SIGB	1,768,508	-208,295	99.2	CS
FIT + SIG	1,699,373	-277,430	99.9	CS
COL	1,600,155	-376,648	105.5	CS
CTC DoD 3D 6mm 5y	2,156,740	179,938	101.2	1,777
CTC NCTC 2D/3D 6mm 5y	2,172,677	195,874	98.0	1,999

ACER = average cost-effectiveness ratio compared with no screening; LYG = life-years gained compared with no screening; NA = not applicable; CS = cost-saving

#### Appendix 4: Results for the secondary threshold analyses.

**Table A4.1.** Threshold analysis on CT colonography test characteristics for scenarios with a 6 mm colonoscopy referral threshold: unit cost of CT colonography screening test resulting in equal outcomes compared to other recommended CRC screening strategies for different estimates of CT colonography test characteristics

CTC outcome	Base cases		Sensitivity analysis, interval 10 years		Sensitivity analysis, test characteristics †	
	CTC DoD 3D 6mm	CTC NCTC 2D/3D 6mm	CTC DoD 3D 6mm	CTC NCTC 2D/3D 6mm	CTC WC 2D/3D 6mm	CTC DoD 2D 6mm
On efficient frontier	122, <b>196</b> , 199	108, 183, <b>205</b>	52, 266, <b>352</b>	83, 241‡, <b>371</b>	25, 83‡, <b>173</b>	98, 163‡, <b>246</b>
Cost-neutral vs. no screening	76, 323, <b>398</b>	105, 324, <b>398</b>	114, 482, <b>599</b>	143, 473, <b>599</b>	38, 251, <b>336</b>	112, 308, <b>393</b>
Equal to colonoscopy ACER	179, <b>210</b> , 221	194, <b>227</b> , 237	244, <b>330</b> , 348	258, <b>339</b> , 356	175, <b>206</b> , 248	246, <b>328</b> , 337

ACER = average cost-effectiveness ratio compared with no screening (calculated using discounted costs and life-years gained)

\* MISCAN values in plain text; SimCRC values in italics; CRC-SPIN values in bold

† See Table 7 for the test characteristics used in these scenarios

‡ CTC strategy is on the frontier as the least effective and least costly non-dominated strategy if the cost is at most this amount

**Table A4.2.** Threshold analysis on CT colonography test characteristics for scenarios with a 10 mm colonoscopy referral threshold: unit cost of CT colonography screening test resulting in equal outcomes compared to other recommended CRC screening strategies for different estimates of CT colonography test characteristics

CTC outcome	Sensitivity analysis scenarios with 10mm colonoscopy referral thresholds					
	Primary 3D reads		2D/3D reads		Primary 2D reads	
	CTC DoD 3D 10mm	CTC J 3D 10mm	CTC NCTC 2D/3D 10mm	CTC WC 2D/3D 10mm	CTC DoD 2D 10mm	CTC J 2D 10mm
On efficient frontier	98, <b>132</b> ‡, 192‡	71, <b>105</b> ‡, 153‡	49, <b>90</b> ‡, 135‡	10, <b>43</b> ‡, 81‡	75, <b>110</b> ‡, 160‡	73, <b>105</b> ‡, 154‡
Cost-neutral vs. no screening	118, 327, <b>329</b>	106, 284, <b>297</b>	68, 284, <b>309</b>	43, 232, <b>265</b>	110, 290, <b>301</b>	107, 284, <b>296</b>
Equal to colonoscopy ACER	<b>178</b> , 187, 259	<b>151</b> , 167, 228	<b>142</b> , 145, 210	<b>96</b> , 115, 166	<b>155</b> , 170, 233	<b>150</b> , 167, 229

ACER = average cost-effectiveness ratio compared with no screening (calculated using discounted costs and life-years gained)

\* MISCAN values in plain text; SimCRC values in italics; CRC-SPIN values in bold

† See Table 7 for the test characteristics used in these scenarios

‡ CTC strategy is on the frontier as the least effective and least costly non-dominated strategy if the cost is at most this amount

**Table A4.3.** Threshold analysis on CT colonography adherence: unit cost of CT colonography screening test resulting in equal outcomes compared to other recommended CRC screening strategies for different levels of adherence with CT colonography screening\*

CTC outcome	Base case (CTC DoD 3D 6mm 5y)	Sensitivity Analysis on CTC Adherence†	
	Adherence 50% for all strategies	CTC adherence 55%	CTC adherence 62.5%
On efficient frontier	122, <b>196</b> , <i>199</i>	293‡, <b>360</b> ‡, <i>408</i> ‡	547‡, <b>668</b> ‡, <i>694</i> ‡
Cost-neutral vs. no screening	76, <i>323</i> , <b>398</b>	76, <i>323</i> , <b>398</b>	76, <i>323</i> , <b>398</b>
Equal to colonoscopy ACER	179, <b>210</b> , <i>221</i>	179, <b>210</b> , <i>221</i>	179, <b>210</b> , <i>221</i>

ACER = average cost-effectiveness ratio compared with no screening (calculated using discounted costs and life-years gained)

\* MISCAN values in plain text; SimCRC values in italics; CRC-SPIN values in bold

† Strategies other than CTC remain at 50% adherence

‡ CTC strategy is on the frontier with an incremental cost-effectiveness ratio (ICER) of \$50,000 if the cost is at least this amount

**Table A4.4.** Threshold analysis from modified societal perspective: unit costs for CT colonography screening test resulting in equal outcomes compared to other recommended CRC screening strategies for modified societal perspective

CTC outcome	Total threshold costs (includes co-payments and patient time costs)		CMS payment rates (excludes co-payments and patient time costs)	
	CTC DoD 3D 6mm	CTC NCTC 2D/3D 6mm	CTC DoD 3D 6mm	CTC NCTC 2D/3D 6mm
On efficient frontier	181, <b>318</b> , 332	154, 324, <b>336</b>	26, <b>163</b> , 177	NT, 169, <b>181</b>
Cost-neutral vs. no screening	NT, 288, <b>406</b>	12, 321, <b>432</b>	NT, 133, <b>250</b>	NT, 166, <b>277</b>
Equal to colonoscopy ACER	215, <b>340</b> , 347	234, 371, <b>372</b>	60, <b>185</b> , 191	79, 216, <b>217</b>

ACER = average cost-effectiveness ratio compared with no screening (calculated using discounted costs and life-years gained); NT = no threshold found (i.e., negative CTC test cost)

\* MISCAN values in plain text; SimCRC values in italics; CRC-SPIN values in bold

†CTC strategy is on the frontier as the least effective and least costly non-dominated strategy if the cost is at most this amount

**Table A4.5.** Threshold analysis on CT colonography adherence: unit cost of CT colonography screening test resulting in equal outcomes compared to other recommended CRC screening strategies for different levels of payment of anesthesia\*

CTC outcome	Base case (CTC DoD 3D 6mm 5y)	Sensitivity Analysis on CTC Adherence†	
	No payment	29% payment	100% payment
On efficient frontier	122, <b>196</b> , <i>199</i>	119, <i>199</i> , <b>204</b>	114, <i>198</i> , <b>221</b>
Cost-neutral vs. no screening	76, <i>323</i> , <b>398</b>	57, <i>307</i> , <b>385</b>	12, <i>268</i> , <b>353</b>
Equal to colonoscopy ACER	179, <b>210</b> , <i>221</i>	186, <b>220</b> , <i>229</i>	205, <b>243</b> , <i>250</i> ,

ACER = average cost-effectiveness ratio compared with no screening (calculated using discounted costs and life-years gained)

\* MISCAN values in plain text; SimCRC values in italics; CRC-SPIN values in bold

† Strategies other than CTC remain at 50% adherence

‡ CTC strategy is on the frontier with an incremental cost-effectiveness ratio (ICER) of \$50,000 if the cost is at least this amount

## Appendix 5: Results for a cohort of 50-year-olds.

**Table A.5.1.** Discounted costs and life-years gained per 1000 50-year-olds without CRC screening and with 14 CRC screening strategies and associated incremental cost-effectiveness ratios

Strategy	MISCAN			SimCRC			CRC-SPIN		
	Discounted Costs (\$)	Discounted LYG	ICER (\$)	Discounted Costs (\$)	Discounted LYG	ICER (\$)	Discounted Costs (\$)	Discounted LYG	ICER (\$)
No screening	2,320,612	0.0	---	2,066,811	0.0	d	1,685,545	0	d
HII	2,369,426	85.4	571	1,631,942	102.3	---	1,299,145	84.1	---
HS	2,615,292	100.2	16,605	1,742,331	124.9	4,904	1,445,618	105.9	6,727
FIT	2,688,092	99.7	d	1,821,510	123.6	d	1,537,215	103.5	d
SIGB	2,725,559	89.2	d	1,925,847	96.7	d	1,724,857	85.9	d
SIG	2,760,602	92.2	d	1,935,992	104.5	d	1,656,998	93.2	d
HII + SIGB	2,832,410	103.0	d	1,847,372	127.8	d	1,717,055	107.0	d
HII + SIG	2,823,342	102.9	d	1,865,864	129.3	d	1,674,508	109.0	d
HS + SIGB	2,952,372	104.8	73,336	1,974,606	133.7	26,215	1,731,501	113.2	d
HS + SIG	2,933,686	104.4	d	1,997,694	134.1	54,647	1,702,870	113.6	33,413
FIT + SIGB	3,151,945	105.6	272,160	2,099,318	133.9	d	1,921,951	112.7	d
FIT + SIG	3,058,485	105.0	d	2,127,049	134.4	503,405	1,859,241	113.4	d
COL	3,011,165	101.8	d	2,090,696	132.5	d	1,818,835	116.7	d
CTC DoD 3D 6mm 5y*	3,685,253	100.6	d	2,692,564	131.4	d	2,477,458	112.9	d
CTC NCTC 2D/3D 6mm 5y*	3,751,074	96.1	d	2,752,347	126.6	d	2,521,670	109.9	d

--- indicates default strategy (i.e., the least costly and least effective non-dominated strategy)

LYG = life-years gained vs. no screening; ICER = incremental cost-effectiveness ratio; d = dominated

\* The two CTC strategies are not competing options; they represent a range of estimates of CTC test characteristics. They are shown here together for comparison purposes only. The ICERs are assessed separately using each CTC strategy in turn.

**Table A.5.2.** Threshold analysis on CT colonography test characteristics: unit cost of CT colonography screening test resulting in equal outcomes compared to other recommended CRC screening strategies for CRC screening beginning at age 50\*

CTC outcome	Screening and counting from age 50	
	CTC DoD 3D 6mm 5y	CTC NCTC 2D/3D 6mm 5y
	<i>5-yearly CTC screening</i>	
On efficient frontier	72, 167, <b>179</b>	79, 148, <b>174</b>
Cost-neutral vs. no screening	NT, <b>182</b> , 230	2, <b>210</b> , 246
Equal to colonoscopy ACER	216, <b>234</b> , 240	224, 254, <b>255</b>

ACER = average cost-effectiveness ratio compared with no screening (calculated using discounted costs and life-years gained)

\* MISCAN values in plain text; SimCRC values in italics; CRC-SPIN values in bold

† CTC strategy is on the frontier as the least effective and least costly non-dominated strategy if the cost is at most this amount

**Appendix 6.** Derivation of costs per screening test by point of service for frequency weights, CPT codes and resulting cost estimates, as reported in the CISNET report to CMS on DNA stool testing (25)

**Table A.6.1.** CPT codes for screening with flexible sigmoidoscopy and colonoscopy.

CPT code	Description
Flexible sigmoidoscopy (no polyp)	
45330	Diagnostic sigmoidoscopy
G0104	CA screen; flexible sigmoidoscope
Flexible sigmoidoscopy (with biopsy)*	
45331	Sigmoidoscopy and biopsy
Colonoscopy (without polypectomy)	
45378	Diagnostic colonoscopy
G0105	Colon screen in high risk individuals
G0121	Colon cancer screening for non high risk individual
Colonoscopy (with polypectomy)	
45380	Colonoscopy and biopsy
45381	Colonoscopy, submucous injection
45382	Colonoscopy/control bleeding
45383	Lesion removal colonoscopy -fulguration
45384	Lesion remove colonoscopy-hot biopsy
45385	Lesion removal colonoscopy-snare polypectomy
Pathology	
88305	Tissue examination by pathologist

\* Under the assumption that there is no polypectomy associated with flexible sigmoidoscopy.

**Table A.6.2.** Ambulatory surgery center (ASC) payment rates

CPT Code	ASC Payment, \$			PFS*- Facility, \$			Total ASC (ASC Payment + PFS), \$		
	Total (B+M)	Beneficiary (B)	Medicare (M)	Total (B+M)	Beneficiary (B)	Medicare (M)	Beneficiary (B)	Medicare (M)	Societal Costs (B+M)
Flexible sigmoidoscopy without biopsy									
45330	NA	NA	NA	56.0	11.2	44.8	NA	44.8	NA
G0104	NA	NA	NA	56.0	11.2	44.8	NA	44.8	NA
Flexible sigmoidoscopy with biopsy									
45331	299.2	59.8	239.4	67.0	13.4	53.6	73.2	293.0	366.2
Colonoscopy without polypectomy									
45378	446	89.2	356.8	197.0	39.4	157.6	128.6	514.4	643
G0105	446	111.5	334.5	197.0	39.4	157.6	150.9	492.1	643
G0121	446	111.5	334.5	197.0	39.4	157.6	150.9	492.1	643
Colonoscopy with polypectomy									
45380	446	89.2	356.8	235.0	47.0	188.0	136.2	544.8	681
45381	446	89.2	356.8	222.0	44.4	177.6	133.6	534.4	668
45382	446	89.2	356.8	299.0	59.8	239.2	149	596	745
45383	446	89.2	356.8	307.0	61.4	245.6	150.6	602.4	753
45384	446	89.2	356.8	247.0	49.4	197.6	138.6	554.4	693
45385	446	89.2	356.8	279.0	55.8	223.2	145	580	725
Pathology									
88305	NA	NA	NA	NA	NA	NA	NA	NA	NA

\* Physician fee schedule

**Table A.6.3.** Outpatient prospective payment system (OPPS) payment rates

CPT Code	OPPS Payment, \$			PFS- Facility, \$			Total OPPS (OPPS Payment + PFS), \$		
	Total (B+M)	Beneficiary (B)	Medicare (M)	Total (B+M)	Beneficiary (B)	Medicare (M)	Beneficiary (B)	Medicare (M)	Societal Cost (B+M)
Flexible sigmoidoscopy without biopsy									
45330	299.24	64.4	234.84	56	11.2	44.8	75.6	279.64	355.24
G0104	224.92	56.23	168.69	56	11.2	44.8	67.43	213.49	280.92
Flexible sigmoidoscopy with biopsy									
45331	299.24	64.4	234.84	67	13.4	53.6	77.8	288.44	366.24
Colonoscopy without polypectomy									
45378	538.99	186.06	352.93	197	39.4	157.6	225.46	510.53	735.99
G0105	446	111.5	334.5	197	39.4	157.6	150.9	492.1	643
G0121	446	111.5	334.5	197	39.4	157.6	150.9	492.1	643
Colonoscopy with polypectomy									
45380	538.99	186.06	352.93	235	47	188	233.06	540.93	773.99
45381	538.99	186.06	352.93	222	44.4	177.6	230.46	530.53	760.99
45382	538.99	186.06	352.93	299	59.8	239.2	245.86	592.13	837.99
45383	538.99	186.06	352.93	307	61.4	245.6	247.46	598.53	845.99
45384	538.99	186.06	352.93	247	49.4	197.6	235.46	550.53	785.99
45385	538.99	186.06	352.93	279	55.8	223.2	241.86	576.13	817.99
Pathology									
88305	32.03	10.84	21.19	38	7.6	30.4	18.44	51.59	70.03

**Table A.6.4. Office payment rates**

CPT Code	PFS- Office Total (B+M), \$	PFS- Office Beneficiary (B), \$	PFS- Office Medicare (M), \$
Flexible sigmoidoscopy without biopsy			
45330	124	24.8	99.2
G0104	124	24.8	99.2
Flexible sigmoidoscopy with biopsy			
45331	160	32	128
Colonoscopy without polypectomy			
45378	372	74.4	297.6
G0105	372	74.4	297.6
G0121	372	74.4	297.6
Colonoscopy with polypectomy			
45380	442	88.4	353.6
45381	429	85.8	343.2
45382	590	118	472
45383	524	104.8	419.2
45384	436	87.2	348.8
45385	498	99.6	398.4
Pathology			
88305	103	20.6	82.4

**Table A.6.5.** Select OPPS, ASC, and office payment rates with the addition of pathology costs (when applicable)

CPT Code	Total ASC				Total OPPS				Total PFS			
	Beneficiary	Medicare	Beneficiary with pathology review†	Medicare with pathology review†	Beneficiary	Medicare	Beneficiary with pathology review	Medicare with pathology review	Beneficiary	Medicare	Beneficiary with pathology review	Medicare with pathology review
Flexible sigmoidoscopy without biopsy												
45330	NA	NA			75.6	279.6			24.8	99.2		
G0104	NA	NA			67.4	213.5			24.8	99.2		
Flexible sigmoidoscopy with biopsy												
45331	73.2	293.0	101.7	406.7	77.8	288.4	103.2	359.6	32	128	60.4	241.7
Colonoscopy without polypectomy												
45378	128.6	514.4			225.46	510.5			74.4	297.6		
G0105	150.9	492.1			150.9	492.1			74.4	297.6		
G0121	150.9	492.1			150.9	492.1			74.4	297.6		
Colonoscopy with polypectomy												
45380	136.2	544.8	164.6	658.5	233.1	540.9	258.5	612.1	88.4	353.6	116.8	467.3
45381	133.6	534.4	162.0	648.1	230.5	530.5	255.9	601.7	85.8	343.2	114.2	456.9
45382	149	596	177.4	709.7	245.9	592.1	271.3	663.3	118.0	472	146.4	585.7
45383	150.6	602.4	179.0	716.1	247.5	598.5	272.9	669.7	104.8	419.2	133.2	532.9
45384	138.6	554.4	167.0	668.1	235.5	550.5	260.9	621.7	87.2	348.8	115.6	462.5
45385	145	580	173.4	693.7	241.9	576.1	267.3	647.3	99.6	398.4	128.0	512.1

\* All values shown in 2007 dollars.

† In the ASC setting pathology review is farmed out to external labs, for which PFS Office rates apply.

**Table A.6.6.** Percent of procedures by place of service (PoS), weights per place of service, and cost of individual procedures weighted by place of service

CPT Code	ASC % of proce- dures by PoS (a)	OPPS % of procedures by PoS (b)	Office % of proce- dures by PoS (c)	Total % (d = a+b+c)	ASC Weight* (a/d)	OPPS Weight* (b/d)	Office Weight * (c/d)	Beneficiary weighted cost by PoS ** (B)	Medicare weighted cost by PoS ** (M)	Society weighted cost by PoS (B+M)
Flexible sigmoidoscopy without biopsy										
45330	0	26.22	43.26	69.48	0	0.38	0.62	43.97	167.29	211.26
G0104	0	22.08	72.86	94.94	0	0.23	0.77	34.71	125.78	160.49
Flexible sigmoidoscopy with biopsy										
45331	24	27	16.09	67.09	0.36	0.40	0.24	82.17	348.19	430.37
Colonoscopy without polypectomy										
45378	42.78	40.26	4.18	87.22	0.49	0.46	0.05	170.71	502.22	672.94
G0105	53.11	43.32	2.84	99.27	0.54	0.44	0.03	148.71	486.54	635.25
G0121	50.95	44.53	3.22	98.7	0.52	0.45	0.03	148.40	485.75	634.16
Colonoscopy with polypectomy										
45380	47.26	38.13	3.29	88.68	0.53	0.43	0.04	192.28	631.47	823.75
45381	46	40.79	2.32	89.11	0.52	0.46	0.03	192.11	621.90	814.01
45382	20.35	29.84	1.8	51.99	0.39	0.57	0.03	215.63	678.79	894.43
45383	42.25	46.85	4.49	93.59	0.45	0.50	0.05	211.09	684.10	895.19
45384	47.8	44.6	3.02	95.42	0.50	0.47	0.03	197.39	639.92	837.31
45385	48.49	41.48	3.75	93.72	0.52	0.44	0.04	201.90	665.91	867.81

Out of ASC, OPSS, and office.

\*\* Weighted average of costs from table 5 including pathology (if applicable) by PoS

**Table A.6.7.** Costs of flexible sigmoidoscopy and colonoscopy with and without polyps\*

CPT Code	Beneficiary Weighted Cost by PoS (B)	Medicare Weighted Cost by PoS (M)	Society Weighted Cost by PoS (B+M)	Total number of procedures per HCPCS code	Weights by HCPCS code (w)	Weighted Beneficiary Costs by PoS and HCPCS code (w*B)	Weighted Medicare Costs by PoS and HCPCS code (w*M)	Weighted Society Costs by PoS and HCPCS code (w*(B+M))
Flexible sigmoidoscopy without biopsy								
45330	43.97	167.29	211.26	74,032	0.84	37.07	141.06	178.13
G0104	34.71	125.78	160.49	13,770	0.16	5.44	19.73	25.17
<b>Total</b>						<b>42.52</b>	<b>160.78</b>	<b>203.30</b>
Flexible sigmoidoscopy with biopsy								
45331	82.17	348.19	430.37	29,349	1.00	82.17	348.19	430.37
<b>Total</b>						<b>82.17</b>	<b>348.19</b>	<b>430.37</b>
Colonoscopy without polypectomy								
45378	170.71	502.22	672.94	1,270,881	0.71	121.76	358.21	479.97
G0105	148.71	486.54	635.25	208,073	0.12	17.37	56.82	74.18
G0121	148.40	485.75	634.16	302,860	0.17	25.22	82.57	107.79
<b>Total</b>						<b>164.35</b>	<b>497.59</b>	<b>661.94</b>
Colonoscopy with polypectomy								
45380	192.28	631.47	823.75	879,279	0.38	73.70	242.05	315.76
45381	192.11	621.90	814.01	33,907	0.01	2.84	9.19	12.03
45382	215.63	678.79	894.43	12,530	0.01	1.18	3.71	4.89
45383	211.09	684.10	895.19	89,884	0.04	8.27	26.81	35.08
45384	197.39	639.92	837.31	381,305	0.17	32.81	106.37	139.18
45385	201.90	665.91	867.81	896,966	0.39	78.95	260.39	339.34
<b>Total</b>						<b>197.75</b>	<b>648.52</b>	<b>846.28</b>